Biomarkers for autism spectrum disorders

ABSTRACT

Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.

FIELD OF THE INVENTION

The present invention relates to genetic markers for Autism Spectrum Disorders (ASD).

BACKGROUND OF THE INVENTION

Autism is a heritable neurodevelopmental condition characterized by impairments in social communication and by a preference for repetitive activities. Autism is not a distinct categorical disorder but is the prototype of a group of conditions defined as Pervasive Developmental Disorders (PDDs) or Autism Spectrum Disorders (ASD), which include Asperger's Disorder, Childhood Disintegrative Disorder, Pervasive developmental disorder-not otherwise specified (PDD-NOS) and Rett Syndrome. ASD is diagnosed in families of all racial, ethnic and social-economic backgrounds with incidence roughly four times higher in males compared to females. Overall population prevalence of autism has increased in recent years to a current estimate of 20 in 10,000 with incidence as high as 60 in 10,000 for all autism spectrum disorders.

Data from several epidemiological twin and family studies provide substantial evidence that autism has a significant and complex genetic etiology. The concordance rate in monozygotic twins is 60-90% (Bailey 1995), and the recurrence rate in siblings of affected probands has been reported to be between 5-10% (Jones & Szatmari 1988) representing a 50 fold increase in risk compared to the general population. Although autism spectrum disorders are among the most heritable complex disorders, the genetic risk is clearly not conferred in simple Mendelian fashion.

In a minority of cases (˜10%), autism is part of a broader recognizable disorder (e.g. fragile X syndrome, tuberous sclerosis) or is associated with cytogenetically-detectable chromosome abnormalities. Moreover, co-morbidity of autism with microdeletion syndromes (e.g. William-Beuren and Sotos) and other genomic disorders (e.g. Prader-Willi/Angelman) suggests chromosomal imbalances are involved in the underlying etiology. The most frequent cytogenetic anomaly is an interstitial, maternally-inherited duplication of 15q11-13 (1-3%) encompassing the Prader Willi/Angelman Syndrome critical region. There are also a large number of cases with deletions in the q11.2 and q13.3 regions of chromosome 22. The 22q11.2 region is associated with velo-cardio-facial Syndrome and deletions at 22q13.3 appear to also represent a clinically definable syndrome. Both deletions are associated with the autistic phenotypes. Other chromosome loci associated with anomalies with a higher frequency of events observed in syndromic forms of ASD include 7q (see TCAG www.chr7.org), 2q37, 5p14-15, 17p11.2. In addition, reciprocal duplications overlapping the William-Beuren deletion region have been associated with the autism phenotype.

Genome-wide linkage scans have found evidence for susceptibility loci on almost all chromosomes with 7q yielding the most consistent results. Other loci with significant linkage include 2q (IMGSAC 2001), 3q and most recently 11p (AGP 10K study). In some instances, like 7q, there is considerable overlap between cytogenetic anomalies and linkage results. However, the lack of linkage found at 15q11-13 and 22q13.3 loci reflect considerable heterogeneity in ASD and suggest that these rearrangements are responsible for a particular ASD subtype involving genes that do not contribute to the phenotype in cytogenetically normal patients. Despite promising results, no specific genes within these linkage peaks have unequivocally been shown to contribute to autism.

Mutations associated with ASD have been reported in two neuroligin (NLGN3 and NLGN4) genes and more recently SHANK3; however, these account for only rare causes of ASD. Other genes have been implicated, but represent rare events or have not yet been validated by other studies.

Together these data suggest substantial genetic heterogeneity with the most likely cause of non-syndromic idiopathic ASD involving multiple epistatically-interacting loci.

The identification of large scale copy number variants (CNVs) represents a considerable source of genetic variation in the human genome that contributes to phenotypic variation and disease susceptibility found small inherited deletions in autistic kindreds suggesting possible susceptibility loci.

It would be desirable to identify genetic markers of ASD that facilitate in a determination of the risk of ASD in an individual, as well as to assist in the diagnosis of the condition.

SUMMARY OF THE INVENTION

A number of genetic markers have now been identified which are useful in assessing the risk of ASD in an individual, as well as being useful to diagnose the condition. The markers are useful both individually and in the form of a microarray to screen individuals for risk of ASD.

Thus, in one aspect of the present invention, a method of determining the risk of ASD in an individual is provided comprising:

probing a nucleic acid-containing sample obtained from the individual for a gene encoding PTCHD1, wherein a determination that the gene comprises a deletion of at least a portion of exon 1 is indicative of a risk of ASD in the individual.

In another aspect of the present invention, a method of determining the risk of ASD in an individual is provided comprising:

probing a nucleic acid-containing sample obtained from the individual for a mutation that modulates the expression of at least one gene selected from the group consisting of PTCHD1, SHANK3, NFIA, DPP6, DPP10, GPR98, PQBP1, ZNF41 and FTSJ1, wherein identification of a mutation that modulates the expression of at least one of said genes is indicative of a risk of ASD.

In another aspect of the invention, a method of determining the risk of ASD in an individual is provided comprising:

screening a biological sample obtained from the individual for abnormal levels of at least one gene product expressed by a gene selected from the group consisting of PTCHD1, SHANK3, NFIA, DPP6, DPP10, GPR98, PQBP1, ZNF41 and FTSJ1, wherein a determination that at least one of said gene products is expressed at a level that varies from the level in a healthy non-ASD individual is indicative of a risk of ASD.

In a further aspect of the invention, a method of determining the risk of ASD in an individual is provided comprising:

screening a nucleic acid-containing sample from the individual for genomic sequence variations that modulate the expression of PTCHD1.

These and other aspects of the present invention are described by reference to the following figures in which:

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a flow chart depicting the methodology used to identify ASD-specific CNVs;

FIG. 2 illustrates a genome-wide distribution of ASD-specific CNVs as described in Table 3;

FIG. 3 illustrates the chromosome 16p11.2 region as depicted in the Autism Chromosome Rearrangement Database;

FIG. 4 illustrates examples of CNVs observed in ASD families including probands having multiple de novo events (a); rearrangements in the SHANK3 gene (b); probands with chromosome X deletions (at PTCHD1) from female carriers (c) or inherited translocations in addition to an unrelated de novo deletion (d); overlapping events in unrelated probands either de novo (e) or inherited (f) at the DPP6 locus; and recurrent de novo events at chromosome 16p11.2 in unrelated probands either gains (h) or losses (g);

FIG. 5 illustrates examples of DPP6 and DPP10 ASD-related CNVs;

FIG. 6 illustrates examples of chromosome 22q11.2 and 16p11.2 ASD-related CNVs;

FIG. 7 illustrates the cDNA sequence (A) of the PTCHD1 gene and the corresponding amino acid sequence (B); and

FIG. 8 illustrates ASD-related missense mutations identified in Table 7.

DETAILED DESCRIPTION OF THE INVENTION

A method of determining the risk of an autism spectrum disorder (ASD) in an individual is provided comprising screening a biological sample obtained from the individual for a mutation that may modulate the expression of at least one gene selected from the group consisting of PTCHD1, SHANK3, NFIA, DPP6, DPP10, DPYD, GPR98, PQBP1, ZNF41 and FTSJ1. Such genes are referred to herein as “ASD-associated” genes.

The term “an autism spectrum disorder” or “an ASD” is used herein to refer to at least one condition that results in developmental delay of an individual such as autism, Asperger's Disorder, Childhood Disintegrative Disorder, Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS) and Rett Syndrome (APA DSM-IV 2000).

In the present method of determining ASD risk in an individual, a biological sample obtained from the individual is utilized. A suitable biological sample may include, for example, a nucleic acid-containing sample or a protein-containing sample. Examples of suitable biological samples include saliva, urine, semen, other bodily fluids or secretions, epithelial cells, cheek cells, hair and the like. Although such non-invasively obtained biological samples are preferred for use in the present method, one of skill in the art will appreciate that invasively-obtained biological samples, may also be used in the method, including for example, blood, serum, bone marrow, cerebrospinal fluid (CSF) and tissue biopsies such as tissue from the cerebellum, spinal cord, prostate, stomach, uterus, small intestine and mammary gland samples. Techniques for the invasive process of obtaining such samples are known to those of skill in the art. The present method may also be utilized in prenatal testing for the risk of ASD using an appropriate biological sample such as amniotic fluid and chorionic villus.

In one aspect, the biological sample is screened for nucleic acid encoding selected genes in order to detect mutations associated with an ASD. It may be necessary, or preferable, to extract the nucleic acid from the biological sample prior to screening the sample. Methods of nucleic acid extraction are well-known to those of skill in the art and include chemical extraction techniques utilizing phenol-chloroform (Sambrook et al., 1989), guanidine-containing solutions, or CTAB-containing buffers. As well, as a matter of convenience, commercial DNA extraction kits are also widely available from laboratory reagent supply companies, including for example, the QIAamp DNA Blood Minikit available from QIAGEN (Chatsworth, Calif.), or the Extract-N-Amp blood kit available from Sigma (St. Louis, Mo.).

Once an appropriate nucleic acid sample is obtained, it is subjected to well-established methods of screening, such as those described in the specific examples that follow, to detect genetic mutations indicative of ASD, i.e. ASD-linked mutations. Mutations, such as genomic copy number variations (CNVs), which include gains and deletions of segments of DNA, for example, segments of DNA greater than about 1 kb, such as DNA segments between about 300 and 500 kb, as well as base pair mutations such as nonsense, missense and splice site mutations, including sequence mutations in both coding and regulatory regions of a gene, have been found to be indicative of ASD.

ASD-linked mutations such as CNVs are not restricted to a single chromosome, but rather have been detected on a multiple chromosomes such as the X chromosome, chromosome 15 and chromosome 21, and on various regions of the same chromosome such as at Xp11 and Xp22. Examples of CNVs that have been determined to be linked to ASD include a deletion on chromosome Xp22 including at least a portion of exon 1 of the PTCHD1 gene; a duplication on chromosome 15q11; and a deletion within the SHANK3 gene.

Genomic sequence variations of various types in different genes have been identified as indicative of ASD. CNVs in the DPP10 gene, including intronic gains, such as a 105 kb intronic gain, and exonic losses, such as a 478 kb exonic loss, both of which are more specifically identified in Table 1, have been identified; CNVs in the DPP6 gene, such as a 66 kb loss encompassing exons 2 and 3 and gains such as a CNV encompassing the entire DPP6 gene, a 270 kb exonic gain (exon 1), and a 16 kb intronic gain (see Table 1); CNVs in the SHANK3 gene such as a 276 kb loss; and CNVs in the DYPD gene such as a loss of the entire gene.

In one embodiment, genomic sequence variations that inhibit the expression of PTCHD1 have been linked to ASD. The terminology “inhibit expression” refers broadly to sequence variations that may inhibit, or at least reduce, any one of transcription and/or translation, as well as the activity of the PTCHD1 protein. For example, a CNV in the PTCHD1 gene comprising a large deletion of the coding region which results in at least a reduction of the expression of PTCHD1 protein has been found to be indicative of ASD. Although the CNV is not particularly restricted, the CNV deletion may include, for example, at least a portion of exon 1, but may additionally include surrounding regions as well, such as intron 1, in whole or in part, or a portion or more of the upstream region thereof.

Genomic sequence variations other than CNVs have also been found to be indicative of ASD, including, for example, missense mutations which result in amino acid changes in a protein that may also affect protein expression. In one embodiment, missense mutations in the PTCHD1 gene have been identified which are indicative of ASD, including missense mutations resulting in the following amino acid substitutions in the Ptchd1 protein: L73F, I173V, V195I, ML336-337II and E479G.

To determine risk of ASD in an individual, it may be advantageous to screen for multiple genomic mutations, including CNVs and other mutations as indicated above applying array technology. In this regard, genomic sequencing and profiling, using well-established techniques as exemplified herein in the specific examples, may be conducted for an individual to be assessed with respect to ASD risk/diagnosis using a suitable biological sample obtained from the individual. Identification of one or more mutations associated with ASD would be indicative of a risk of ASD, or may be indicative of a diagnosis of ASD. This analysis may be conducted in combination with an evaluation of other characteristics of the individual being assessed, including for example, phenotypic characteristics.

In view of the determination of gene mutations which are linked to ASD, a method for determining risk of ASD in an individual is also provided in which the expression or activity of a product of an ASD-linked gene mutation is determined in a biological protein-containing sample obtained from the individual. Abnormal levels of the gene product or abnormal levels of the activity thereof, i.e. reduced or elevated levels, in comparison with levels that exist in healthy non-ASD individuals, are indicative of a risk of ASD, or may be indicative of ASD. Thus, a determination of the level and/or activity of the gene products of one or more of PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1, may be used to determine the risk of ASD in an individual, or to diagnose ASD. As one of skill in the art will appreciate, standard assays may be used to identify and quantify the presence and/or activity of a selected gene product.

Embodiments of the invention are described by reference to the following specific examples which is not to be construed as limiting.

Example 1 DNA Samples and Population Structure

The study included 426 ASD families. All of the index cases met Autism Diagnostic Interview-Revised (ADI-R) and Autism Diagnostic Observation Schedule (ADOS) criteria or on a clinical best estimate (Risi et al. J Am Acad Child Adolesc Psychiatry 2006; 45 (9):1094-103). Thirty-two of these carried a cytogenetic chromosome rearrangement; 18 were detected by karyotyping 328 of 412 samples that originated from child diagnostic centres at the Hospital for Sick Children in Toronto and from St. John's, Newfoundland; 14 were already known to carry karyotypic anomalies (see Table 1 for information on these 32 patients). Affected and unaffected siblings were also assessed, and 56% (237/426) had one child (simplex) and 44% (189/426) had more than one child (multiplex) with ASD. Most cases were screened for fragile X mutations (75%) and if detected they were not included in the study. Most experiments were performed on blood genomic DNA (80%), otherwise the source was cell lines, e.g. lymphoblast cell lines. Population ancestry was estimated using STRUCTURE (Falush et al. Genetics 2003; 164 (4):1567-87; Pritchard et al. Genetics 2000; 155 (2):945-59).

TABLE 1 Cytogenetic Analysis Sample Phenotype/Family Breakpoint CNV Analysis ID type Karyotype Location RefSeq Genes Chr CNV Size (bp) Location 1 NA0008- Simplex family 46, XX, t(2; 6)(q32; p22) 2q33.1: SATB2 2p11.2 Loss 917,200 89,056,400-89,973,600 000 ASD, developmental unknown 200,096,682-200,154,790 (50863L) dyspraxia 6p22.3: No known genes 6p21.33 Gain 54,600 30,134,300-30,188,900 21,561,566-21,644,040 11p13 Gain 54,200 35,332,700-35,386,900 13q21.33 Loss 28,200 69,642,500-69,670,700 14q11.2 Gain 549,300 21,490,300-22,039,600 14q32.33 Loss 64,000 106,152,000-106,216,000 2 NA0005- Simplex family 46, XX, t(4; 5)(q21; q13) 4q21.3 Several 1p13.2 Gain 128,963 112,783,876-112,912,839 000 ASD, seizure unknown 2q37.3 Loss 602,914 242,127,468-242,730,382 (53601L) disorder, obesity, Error! macrocephaly Hyperlink reference not valid. 3q29 Loss 43,033 196,922,636-196,965,669 5q14.2-q14.3: Several 5q15 Loss 48,627 97,076,449-97,125,076 82,802,678-91,285,973 5q21.3 Loss 13,000 109,391,000-109,404,000 8p23.1 Gain 448,146 12,039,387-12,487,533 14q11.2 Gain 223,579 19,272,965-19,496,544 14q11.2 Gain 650,430 21,407,981-22,058,411 15q11.2 Gain 1,642,961 18,446,422-20,089,383 Error! Hyperlink reference not valid. 3 NA0039- Simplex family 46, XX, der(22)t(14; 22)(q32; q13) pat See CNV See CNV 9q32 Gain 498,000 114,038,000-114,536,000 000 ASD, submucous inherited 14q32.33 Gain 1,436,000 104,920,000-106,356,000 (69736) cleft, globally 15q13.3 Gain 502,500 29,796,300-30,298,800 developmentally 22q13.31-q31.33 Loss 3,231,700 46,277,400-49,509,100 delayed, large ears, short forehead, distally tapere fingers, severe pes planovalgus 4 SK0283- Simplex family 47, XX, ring chromosome 1 See CNV See CNV 1p22.3 Gain 23,993 87,417,351-87,441,344 003 ASD de novo 1q21.2-q21.3 Gain 1,451,926 148,095,537-149,547,463 (72309) 3p26.1 Loss 44,458 5,365,506-5,409,964 4p13 Gain 95,508 44,762,996-44,858,504 4q33 Loss 82,224 171,715,627-171,797,851 5q31.3 Loss 355,649 140,658,658-141,014,307 6p12.3 Gain 13,950 46,962,122-46,976,072 7p14.1 Loss 102,939 38,041,635-38,144,574 7q34 Loss 169,191 141,813,948-141,983,139 14q11.2 Loss 583,148 21,455,546-22,038,694 15q11.2 Loss 1,632,769 18,427,103-20,059,872 17q21.31 Loss 140,746 41,570,665-41,711,411 5 SK0044- Simplex family 46, XY, t(1; 2)(p22.1; p23)pat 1p31.1: NEGR1 7p14.1 Gain 85,900 39,828,000-39,913,900 003 ASD der(13; 15)(q10; q10)mat 72,065,578-72,163,007 (50067) inherited 2p24.3: No known genes 12,376,807-12,733,637 13q10: in progress 15q10: in progress 6 SK0182- Simplex family 46 XY, t(1; 9)(q25; p13) 1q24.2: No known genes 2p24.3 Gain 15,100 14,304,500-14,319,600 003 ASD inherited 167,452,268-167,522,136 (52065) 9p12: 45,695,701-45,737,008 No known genes 14q11.2 Gain 288,100 19,204,300-19,492,400 7 SK0335- Simplex Family 46, XX, t(2; 10)(q22; q22.3) 2q23.1: LOC401431, ATP6VOE2 2p13.3 Gain 374,900 70,152,900-70,527,800 003 ASD, mental unknown 148,938,284-149,125,547 (72815) retardation 10q23.31: SLC16A12, PANK1, 3q29 Gain 43,033 196,922,636-196,965,669 91,265,490-91,461,660 MPHOSPH1 5p13.1 Loss 272,618 38,534,384-38,807,002 6p21.32 Gain 162,900 32,344,099-32,506,999 8p23.1 Gain 21,783 12,264,620-12,286,403 9q32 Gain 22,000 114,153,000-114,175,000 14q11.2 Gain 331,503 21,717,112-22,048,615 15q11.2 Gain 1,516,085 18,427,100-19,943,185 16p11.2-11.1 Gain 266,336 34,325,041-34,591,377 17q21.31 Gain 201,731 41,518,102-41,719,833 20p12.1 Loss 27,500 14,973,800-15,001,300 8 SK0126- Multiplex family 46, XY, t(2; 11)(p11.2; q13.3) pat 2p11.2: No known genes 2q34 Loss 3,000 213,013,000-213,016,000 003 ASD inherited 89,117,655-89,158,494 (59144) 11q13.1: POLA2, CDC42EP2, DPF2 64,821,333-64,861,285 9 SK0152- Multiplex family 46, XY, inv(3)(p24; q24), 3p24: not 3p25.1-p24.3 Loss 1,409,600 15,125,800-16,535,400 003 ASD, oral motor t(5; 7)(p15p13) available (41548L) apraxia, poor balance de novo 3q24: not available 3p12.3 Gain 55,000 78,902,000-78,957,000 and coordination, 5p14.3: CDH18 5p15.31-p15.2 Loss 3,429,389 9,275,811-12,705,200 mild hypotonia, walks 19,825,926-19,883,410 with a wide gait, 7p13: 46,618,434-46,733,542 No known genes 6q16.1 Loss 60,058 95,556,287-95,616,345 severe language 7p14.1 Gain 35,243 38,096,725-38,131,968 delay, moderate 10q11.22 Gain 455,130 47,030,119-47,485,249 intellectual disability, 12p11.21 Gain 63,728 31,904,362-31,968,090 some facial features 12q12 Loss 422,842 40,584,198-41,007,040 of Cri du Chat 14q11.2 Gain 491,397 21,584,229-22,075,626 14q32.33 Gain 22,269 106,223,861-106,246,130 15q11.2 Loss 1,632,718 18,446,422-20,079,140 16q21 Loss 91,432 63,768,909-63,860,341 17q21.31 Gain 219,797 41,500,036-41,719,833 18q12.2 Loss 816,914 32,174,061-32,990,975 10 SK0105- Multiplex family 46, XY, inv(4)(p12; p15.3)mat 4p15.3: No known genes 10q11.21 Gain 1,098,400 41,956,500-43,054,900 003 ASD, primarily non- inherited 12,173,445-12,335,572 (27155L) verbal, profound developmental delay 4p12: 44,876,353-46,024,486 GABRG1 (breakpoint region 13q14.2 Gain 162,300 47,414,800-47,577,100 is located in intron 7) 16q21 Loss 56,600 61,854,900-61,911,500 17q21.31 Gain 238,600 41,521,600-41,760,200 11 SK0205- Simplex family 46, XX, del(5)(p15.1) See CNV See CNV 3q29 Gain 96,068 199,226,000-199,322,068 004 ASD de novo 5p15.33-p15.2 Loss 13,800,984    81,949-13,882,933 (56242) 5q15 Loss 70,891 97,054,185-97,125,076 10q11.22 Gain 1,121,866 46,363,383-47,485,249 10q21.3 Loss 29,732 67,747,770-67,777,502 10q26.3 Gain 244,432 135,079,000-135,323,432 14q11.2 Gain 217,035 19,272,965-19,490,000 15q11.2 Gain 1,662,300 18,427,100-20,089,400 17q21.31 Gain 65,845 41,006,823-41,072,668 17q21.31 Gain 187,028 41,521,621-41,708,649 22q11.21 Gain 150,753 17,265,500-17,416,253 12 SK0061- Simplex family 46, XY, t(5; 7)(q15; q31.32) 7q31.31: No known genes No CNV detected 003 ASD, developmental unknown 118,928,065-119,006,076 (44951) delay 5q14.3: No known genes 88,849,193-88,891,151 13 SK0195- Simplex family 46, XY, t(5; 8; 17)(q31.1; q24.1; q21.3) 5q31.1: KLHL3 2p16.1 Gain 47,900 57,314,000-57,361,900 003 ASD de novo 136,979,583-137,038,092 (55310) 8q24.22: No known genes 10q23.1 Loss 17,500 83,772,000-83,789,500 132,448,049-132,512,973 17q21.31: LRRC37A2, ARL17P1, 14q11.2 Gain 288,100 19,204,300-19,492,400 41,893,216-42,093,636 LOC641522, NSF 17q21.31 Gain 644,700 41,521,600-42,166,300 14 SK0133- Simplex family 46, XY, t(6; 7)(p11.2; q22)pat 6p12.1: DST, c6orf65 2q37.1 Gain 314,000 232,076,000-232,390,000 003 ASD inherited 56,805,919-56,967,398 (46012) 7q22.1: No known genes 5q14.3 Gain 633,400 89,492,800-90,126,200 97,933,646-97,973,368 7q33 Loss 3,000 136,255,000-136,258,000 8q23.2 Loss 32,000 111,182,000-111,214,000 9p21.3 Loss 8,200 25,073,900-25,082,100 11q25 Gain 369,000 133,855,000-134,224,000 12q21.33 Gain 19,700 90,807,700-90,827,400 13q21.32 Loss 2,500 65,576,300-65,578,800 15 SK0043- Multiplex family 46, XY, t(6; 9)(q10; q12) 6q11.2-q12: No known genes 8p23.2 Loss 35,040 3,984,190-4,019,230 003 ASD unknown 63,464,452-63,511,410 (29346) 9q21.11: PIP5K1B 15q11.2 Gain 1,713,200 18,376,200-20,089,400 68,599,032-68,682,365 16 SK0181- Simplex family 46, XY, t(6; 14)(q13; q21) 6q12: 69,241,818-69,279,457 No known genes 3p14.1-p13 Loss 5,346,900 65,286,300-70,633,200 004 ASD de novo 14q21.1-q21.2: LRFN5, c14orf155, c14orf28, 4q28.3 Loss 254,000 135,282,000-135,536,000 (52191) 40,807,716-44,806,460 BTBD5, KIAA0423, PRPF39, FKBP3, AK093422, KIAA1596, FANCM, c14orf106 17 SK0083- Simplex family 46, XY, del(7)(q31.1q31.32) 7q31.1: IMMP2L, LRRN3, DOCK4, 1q31.1 Loss 15,000 186,702,000-186,717,000 003 ASD, de novo 108,272,363-108,337,904 ZNF277P, IFRD1 . . . to . . . 2P23.3 Gain 26,300 25,138,000-25,164,300 (50800L) craniosynostosis, 7q31.31: ASZ1, CFTR, CTTNBP2, 4q35.2 Gain 21,314 188,232,000-188,253,314 developmental verbal 119,007,999-119,335,246 LSM8, ANKRD7 6p24.2 Gain 188,500 11,479,600-11,668,100 dyspraxia, motor 7q31.1-q31.31 Loss 11,023,506 108,200,381-119,223,887 delay 7q36.2 Loss 26,297 152,027,450-152,053,747 8q24.21 Gain 48,000 127,951,000-127,999,000 10p11.23 Gain 26,700 30,893,400-30,920,100 14q11.2 Loss 219,458 19,272,965-19,492,423 17q21.31 Loss 117,521 40,897,617-41,015,138 18 SK0131- Simplex family 46, XX, del(7)(q31.2q32.2)(D7S486-, 7q31.1: FOXP2, MDFIC, TFEC, TES, 2p22.2 Gain 67,740 37,848,232-37,915,972 003 Autistic features, D7S522-) de novo, WBS inv-2 113,181,975-113,518,235 CAV2, CAV1 . . . to . . . IRF5, 3p21.31 Gain 52,599 147,754,068-147,806,667 (39989) speech-language de novo TNPO3, TSPAN33, SMO, disorder 7q32.2: FAM40B, KIAA0828 4q31.21 Gain 120,171 145,146,000-145,266,171 (developmental 128,540,690-128,796,716 7p14.1 Gain 147,076 38,096,725-38,243,801 verbal dyspraxia), 7q31.1-q32.2 Loss 15,486,721 113,335,000-128,821,721 dysmorphic features, 8q13.3 Gain 261,985 72,881,221-73,143,206 mild developmental 10q11.22 Gain 455,100 47,030,100-47,485,200 delay, unable to 10q26.2 Gain 91,077 128,501,014-128,592,091 cough/sneeze/laugh 13q21.33 Loss 44,235 69,634,065-69,678,300 spontaneously 14q11.2 Loss 222,786 19,272,965-19,495,751 14q11.2 Gain 637,249 21,462,466-22,099,715 15q11.2 Gain 1,662,280 18,427,103-20,089,383 17q12 Gain 29,984 31,471,515-31,501,499 22q11.22 Gain 810,876 20,772,047-21,582,923 19 SK0002- Simplex family 46, XX, inv(7)(p15.3; q22.1) 7p21.1: No known genes 4q28.3 Gain 765,000 132,195,000-132,960,000 003 ASD, psychosis unknown 18,284,397-18,302,387 (50002) 7q22.3: SPRK2 5p15.1-15.2 Gain 239,100 14,940,400-15,179,500 104,360,659-104,549,945 15q11.2 Gain 1,713,200 18,376,200-20,089,400 20 SK0211- Simplex family 46, XX, inv(7)(q22q34)mat 7q21.3: No known genes 7q22.1 Gain 379,000 100,393,000-100,772,000 003 ASD, mild elevation inherited 96,943,657-96,985,663 (58892) of lactate 7q34: 140,920,721-140,958,207 TAS2R4, TAS2R5 9p21.1 Loss 135,100 30,408,400-30,543,500 21 SK0040- Multiplex family 46, XY, t(7; 8)(p15; q22), t 7p15.3: No known genes 2q37.3 Loss 95,959 242,634,423-242,730,382 003 ASD, ADHD, severe (10; 11)(q26; q23) 21,825,126-21,869,196 (55449) anxiety attacks, unknown 8q22.2: STK3 10q21.3 Loss 144,903 67,734,600-67,879,503 seizures, difficulties 99,652,299-99,823,618 11q22.3 Loss 62,995 104,729,456-104,792,451 with fine and gross 10q26: Multiple genes 14q11.2 Gain 219,458 19,272,965-19,492,423 motor skills 127,985,179-131,365,091 14q11.2 Gain 224,329 21,784,072-22,008,401 11q23: Multiple genes 15q11.2 Gain 1,662,280 18,427,103-20,089,383 109,979,883-111,597,476 22q11.22 Loss 515,645 21,031,117-21,546,762 22q11.23 Gain 269,129 23,975,202-24,244,331 22 SK0145- Simplex family 46, XX, t(7; 11)(q31; q25)mat 7q31.2: No known genes 1p36.11 Gain 192,600 26,231,500-26,424,100 003 ASD inherited 114,573,150-114,611,613 2p24.2 Gain 14,233 17,416,366-17,430,599 (67955) 11q25: No known genes 3p23 Gain 28,509 34,844,620-34,873,129 133,882,647-134,001,155 5p15.33 Gain 3,029,476   165,712-3,195,188 6p22.2 Gain 25,841 25,576,804-25,602,645 7p14.1 Gain 20,412 37,494,999-37,515,411 8q13.3 Gain 28,933 72,911,162-72,940,095 10p12.1 Loss 98,961 27,642,965-27,741,926 12p12.3 Gain 37,831 18,855,833-18,893,664 14q11.2 Gain 464,929 21,551,291-22,016,220 15q23-24.1 Gain 435,603 70,053,228-70,488,831 19q13.43 Gain 308,600 63,476,500-63,785,100 23 SK0031- Simplex family 46, XY, t(7; 13)(q31.3; q21) mat 7q31.2: ST7 5p13.2 Loss 3,000 36,495,800-36,498,800 003 ASD, very little inherited 116,270,156-116,458,896 6p22.1-21.33 Gain 79,600 29,967,200-30,046,800 (68160L) language, global 13q21.1: No known genes 9p23 Loss 112,800 11,895,600-12,008,400 developmental delays 54,559,087-54,739,454 14q32.2 Gain 772,400 99,015,100-99,787,500 15q11.2 Gain 1,378,000 18,711,400-20,089,400 17q21.31 Gain 597,300 41,569,000-42,166,300 22q11.23 Gain 251,200 23,989,000-24,240,200 24 SK0073- Simplex family 47, XX, idic(15)q13) 15q13: 28,918,525-31,848,963 LOC400968, LOC283755, 1q25.2 Gain 424,000 176,522,000-176,946,000 003 ASD, developmental de novo POTE15, OR4M2, 2p23.3 Gain 703,500 24,701,300-25,404,800 (57283L) delay, delayed OR4N4 . . . to . . . 4p16.3 Gain 997,460 1,692,240-2,689,700 expressive and ARHGAP11A, c15orf45, 4q35.1 Gain 311,000 185,856,000-186,167,000 receptive language GREM1, RYR3 5q31.1 Gain 93,000 134,426,000-134,519,000 9p21.1 Loss 362,900 30,452,800-30,815,700 14q11.2 Gain 414,900 21,660,700-22,075,600 15q11.2-13.3 Gain 11,922,600 18,376,200-30,298,800 16p11.2 Gain 1,543,900 28,062,200-29,606,100 16p11.2 Gain 658,600 30,589,900-31,248,500 25 SK0218- Multiplex family 46, XX, del(18)(q21) 18q21.32: See CNV 12p13.33 Loss 92,328 1,760,084-1,852,412 003 ASD, cleft palate, de novo 55,690,398-55,884,029 (60340) club feet, mild-facial hypoplasia, heart 15q11.2 Loss 1,613,450 18,446,422-20,059,872 defect 17q21.31 Gain 190,234 41,518,415-41,708,649 18q21.32-q23 Loss 20,358,999 55,756,601-76,115,600 19q13.42 Loss 68,786 59,971,717-60,040,503 20p11.23 Gain 128,457 19,740,012-19,868,469 26 SK0215- Simplex family 46, XY, t(19; 21)(p13.2; q22.12) 19p13.2: EVI5L, FLJ22184, LRRC8E, 1p21.3 Loss 1,092,500 97,271,600-98,364,100 006 ASD inherited 7,804,294-7,896,711 MAP2K7, SNAPC2, CTXN1 (58449) 21q22.12: No known genes 17p11.1-p11.2 Gain 503,100 21,634,900-22,138,000 36,091,999-36,191,098 27 SK0136- Simplex family 46, X, der(Y)t(Y; 15) (q12; p11.2) pat Not available 4p13 Gain 42,400 44,809,500-44,851,900 003 ASD inherited 8p23.2 Gain 234,580 2,335,310-2,569,890 (51253) 8q24.23 Loss 138,000 137,757,000-137,895,000 10p12.1 Loss 51,400 27,690,500-27,741,900 15q11.2 Loss 558,300 18,676,700-19,235,000 15q26.3 Gain 388,100 99,827,900-100,216,000 28 SK0243- Simplex Family 46, XY, del(15)(q23q24.2) See CNV See CNV 1q21.1 Loss 333,539 145,700,996-146,034,535 003 ASD de novo 2p22.2 Gain 52,951 37,847,789-37,900,740 (67941) 3q27.3 Gain 91,422 187,897,578-187,989,000 7p22.3 Gain 29,778 141,322-171,100 7p14.1 Loss 32,636 38,092,579-38,125,215 10p13 Loss 1,570 13,096,593-13,098,163 11p15.1 Gain 21,766 18,905,796-18,927,562 15q23-q24.2 Loss 4,289,500 69,601,300-73,890,800 17q12 Gain 38,247 31,463,252-31,501,499 17q21.31 Gain 83,359 41,636,474-41,719,833 29 SK0245- Simplex Family 46, XY, trp(15)(q11.2q13) See CNV See CNV 6q14.1 Loss 47,288 79,036,117-79,083,405 005 ASD, epicanthal de novo 7p14.1 Loss 57,861 38,067,354-38,125,215 (68517) folds, drooping eyes 10p13 Loss 2,538 13,095,625-13,098,163 11p15.1 Loss 12,459 18,905,796-18,918,255 14q11.2 Loss 219,458 19,272,965-19,492,423 14q32.33 Gain 27,408 106,223,861 106,251,269 15q11.2-q13.3 Gain 11,871,747 18,427,100 30,298,847 19p13.2 Loss 132,251 6,902,567 7,034,818 30 NA0097- Simplex Family 46, XX, t(11; 12)(q23.3; p13.3) 11q23: not 2p25.3-2p15 Gain 63,451,406^(b) 2,994 63,454,400 000 ASD unknown available 3p24.2 Loss 159,273 25,980,400-26,139,673 (82361L) 12p11.21 Gain 236,006 31,065,545-31,301,551 12p13.32-p13.31: Multiple genes 14q11.2 Gain 489,269 21,498,204 21,987,473 4,341,718-7,918,138 Xp22.33-Xp22.31 Loss 5,825,311 34,419-5,859,730 31 SK0300- Multiplex Family 46, X, inv(Y)(p11.2q11.2)pat Not available 4p16.1 Gain 35,832 7,801,488-7,837,320 003 ASD, NF1 inherited 5p15.33 Gain 124,630 752,190-876,820 (77447) 6p25.1 Loss 215,567 4,200,904-4,416,471 8q24.23 Loss 198,193 137,757,137-137,955,330 11p15.4 Loss 54,390 6,845,440-6,899,830 14q11.2 Loss 229,676 19,272,965-19,502,641 15q11.2 Loss 1,908,356 18,427,103-20,335,459 Error! Hyperlink reference not valid. 15q21.2 Gain 183,903 48,583,127-48,767,030 Xp11.23 Loss 83,750 47,643,250-47,727,000 32 SK0094- Multiplex Family 46, XX, ins(21; ?)(p11.2; ?) Not available 7q21.2 Loss 509,800 90,919,200-91,429,000 005 ASD unknown (49304) 9q32 Gain 211,000 112,463,000-112,674,000 10q11.22 Gain 124,800 47,030,100-47,154,900 14q32.33 Gain 186,000 105,829,000-106,015,000 Xq23 Loss 888,000 112,325,000-113,213,000 Cytogenetic Analysis Sample Phenotype/Family Breakpoint CNV Analysis ID type Karyotype Location RefSeq Genes AS/Str^(a) RefSeq Genes Comments 1 NA0008- Simplex family 46, XX, t(2; 6)(q32; p22) 2q33.1: SATB2 No/NS No known genes NFLD 000 ASD, developmental unknown 200,096,682-200,154,790 (50863L) dyspraxia 6p22.3: No known genes Yes/NS ZNRD1, 21,561,566-21,644,040 PPP1R11, RNF39, TRIM31 No/NS SLC1A2 No/NS No known genes No/NS No known genes No/NS No known genes 2 NA0005- Simplex family 46, XX, t(4; 5)(q21; q13) 4q21.3 Several Yes/NS ST7L, CAPZA1 NFLD 000 ASD, seizure unknown No/S 10 genes (53601L) disorder, obesity, macrocephaly No/NS MUC20, MUC4 5q14.2-q14.3: Several No/NS No known genes 82,802,678-91,285,973 Yes/NS No known genes No/S FAM86B1, DEFB130, LOC440053 No/S 6 OR genes No/S No known genes No/NS LOC283755, POTE15, OR4M2, OR4N4 3 NA0039- Simplex family 46, XX, der(22)t(14; 22)(q32; q13) pat See CNV See CNV No/NS 7 genes NFLD 000 ASD, submucous inherited No/NS 6 genes Unaffected sibling (69736) cleft, globally No/NS CHRNA7 with ADHD has developmentally Yes/NS 40 genes + 46, XX, der(14) delayed, large ears, SHANK3 t(14; 22)(q32; q13) short forehead, distally tapere fingers, severe pes planovalgus 4 SK0283- Simplex family 47, XX, ring chromosome 1 See CNV See CNV Yes/NS No known genes SK 003 ASD de novo Yes/S 36 genes (72309) Yes/S No known genes Yes/S No known genes Yes/NS No known genes Yes/NS 6 genes No/NS GPR116 No/NS STARD3NL, TARP No/NS PRSS1 No/S No known genes No/S LOC283755, POTE15, OR4M2, OR4N4 No/NS KIAA1267 5 SK0044- Simplex family 46, XY, t(1; 2)(p22.1; p23)pat 1p31.1: NEGR1 No/NS CDC2L5 SK 003 ASD der(13; 15)(q10; q10)mat 72,065,578-72,163,007 (50067) inherited 2p24.3: No known genes 12,376,807-12,733,637 13q10: in progress 15q10: in progress 6 SK0182- Simplex family 46 XY, t(1; 9)(q25; p13) 1q24.2: No known genes No/NS No known genes SK 003 ASD inherited 167,452,268-167,522,136 Younger brother (52065) 9p12: 45,695,701-45,737,008 No known genes No/S 6 genes has the same translocation and severe speech and language disorder but does not meet ASD criteria on ADOS. 7 SK0335- Simplex Family 46, XX, t(2; 10)(q22; q22.3) 2q23.1: LOC401431, ATP6VOE2 Yes/NS 6 genes Others 003 ASD, mental unknown 148,938,284-149,125,547 Non-Canadian (72815) retardation 10q23.31: SLC16A12, PANK1, No/NS MUC20, MUC4 family 91,265,490-91,461,660 MPHOSPH1 Yes/S LIFR Yes/NS C6orf10, BTNL2 No/NS No known genes No/S ORM1, ORM2 No/S No known genes No/S LOC283755, POTE15, OR4M2, OR4N4 No/NS No known genes No/S KIAA1267 Yes/S C20orf133 8 SK0126- Multiplex family 46, XY, t(2; 11)(p11.2; q13.3) pat 2p11.2: No known genes Yes/NS ERBB4 Other 003 ASD inherited 89,117,655-89,158,494 Canadian Family (59144) 11q13.1: POLA2, CDC42EP2, DPF2 64,821,333-64,861,285 9 SK0152- Multiplex family 46, XY, inv(3)(p24; q24), 3p24: not Yes/S 12 genes Other 003 ASD, oral motor t(5; 7)(p15p13) available Canadian Family (41548L) apraxia, poor balance de novo 3q24: not available Yes/S ROBO1 Previously and coordination, 5p14.3: CDH18 Yes/S 8 genes described in a mild hypotonia, walks 19,825,926-19,883,410 manuscript by with a wide gait, 7p13: 46,618,434-46,733,542 No known genes No/S No known genes Harvard et al¹. severe language No/NS No known genes The 3p25.1, delay, moderate No/S ANXA8 5p15.31-p15.2 intellectual disability, No/S No known genes and 18q12.2 some facial features Yes/S YAF2, ZCRB1 deletions were of Cri du Chat No/S No known genes identified in No/NS No known genes Harvard, C. et al No/S LOC283755, using BAC CGH. POTE15, The deletion size OR4M2, OR4N4 has been refined Yes/NS No known genes here using SNPs. No/NS KIAA1267 Older sibling also Yes/S KIAA1328, has ASD but has C18orf10, a normal 46, XX FHOD3 karyotype Maternal aunt with schizophrenia and a maternal uncle with Down syndrome 10 SK0105- Multiplex family 46, XY, inv(4)(p12; p15.3)mat 4p15.3: No known genes Yes/NS RET, SK 003 ASD, primarily non- inherited 12,173,445-12,335,572 RASGEF1A, Described (27155L) verbal, profound BMS1L, ZNF11B, previously in developmental delay MGC16291, Vincent et al.² GALNACT-2 Affected brother, 4p12: 44,876,353-46,024,486 GABRG1 (breakpoint region Yes/NS MED4, NUDT15, apparently is located in intron 7) SUCLA2 unaffected mother Yes/NS No known genes and unaffected No/NS KIAA1267 maternal grandfather all have the same inversion. Distal 4p15.3 breakpoint maps ~12 Mb to a region previously indicated to show linkage to autism. 11 SK0205- Simplex family 46, XX, del(5)(p15.1) See CNV See CNV No/NS LMLN, SK 004 ASD de novo LOC348840 FISH analysis with (56242) Yes/S >50 genes subtelomeric No/NS No known genes probe (containing No/S SYT15, ANXA8, D5S2488) was ANXA8L1, consistent with a PPYR1, GPRIN2 terminal deletion No/NS CTNNA3 on 5p. No/S SYCE1; CYP2E1 No/S OR4K1, OR4N2, OR4K5, OR4K2 No/S LOC283755, POTE15, OR4M2, OR4N4 No/S No known genes No/NS KIAA1267 No/S DGCR6, PRODH, DGCR2 12 SK0061- Simplex family 46, XY, t(5; 7)(q15; q31.32) 7q31.31: No known genes No CNV detected Other 003 ASD, developmental unknown 118,928,065-119,006,076 Non-Canadian (44951) delay 5q14.3: No known genes Family 88,849,193-88,891,151 13 SK0195- Simplex family 46, XY, t(5; 8; 17)(q31.1; q24.1; q21.3) 5q31.1: KLHL3 No/NS No known genes Other 003 ASD de novo 136,979,583-137,038,092 Canadian Family (55310) 8q24.22: No known genes Yes/NS NRG 132,448,049-132,512,973 17q21.31: LRRC37A2, ARL17P1, No/NS OR4K1, OR4N2, 41,893,216-42,093,636 LOC641522, NSF OR4M1, OR4K5, OR4Q3, OR4K2 No/S KIAA1267 14 SK0133- Simplex family 46, XY, t(6; 7)(p11.2; q22)pat 6p12.1: DST, c6orf65 Yes/NS MGC43122, Other 003 ASD inherited 56,805,919-56,967,398 NMUR1, Canadian Family (46012) MGC35154, NCL, CNV seen at B3GNT7 11q25 is in the 7q22.1: No known genes Yes/NS CETN3, same breakpoint 97,933,646-97,973,368 LOC153364, region as Sample POLR3G, SK0145-003 MASS1 No/NS No known genes No/NS No known genes Yes/NS No known genes No/S No known genes Yes/NS No known genes Yes/NS No known genes 15 SK0043- Multiplex family 46, XY, t(6; 9)(q10; q12) 6q11.2-q12: No known genes No/NS CSMD1 SK 003 ASD unknown 63,464,452-63,511,410 Sibling also has (29346) 9q21.11: PIP5K1B No/S LOC283755, ASD but a normal 68,599,032-68,682,365 POTE15, 46, XY karyotype OR4M2, OR4N4 16 SK0181- Simplex family 46, XY, t(6; 14)(q13; q21) 6q12: 69,241,818-69,279,457 No known genes Yes/S 13 genes SK 004 ASD de novo 14q21.1-q21.2: LRFN5, c14orf155, c14orf28, No/NS No known genes (52191) 40,807,716-44,806,460 BTBD5, KIAA0423, PRPF39, FKBP3, AK093422, KIAA1596, FANCM, c14orf106 17 SK0083- Simplex family 46, XY, del(7)(q31.1q31.32) 7q31.1: IMMP2L, LRRN3, DOCK4, No/S No known genes Other 003 ASD, de novo 108,272,363-108,337,904 ZNF277P, IFRD1 . . . to . . . Yes/NS No known genes Canadian Family (50800L) craniosynostosis, 7q31.31: ASZ1, CFTR, CTTNBP2, Yes/S No known genes Described developmental verbal 119,007,999-119,335,246 LSM8, ANKRD7 Yes/NS No known genes previously in Feuk dyspraxia, motor Yes/S >50 genes et al.³ delay Yes/NS No known genes Yes/NS No known genes Yes/NS No known genes No/S OR4K1, OR4N2, OR4M1, OR4K5, OR4Q3, OR4K2 No/NS PLEKHM1 18 SK0131- Simplex family 46, XX, del(7)(q31.2q32.2)(D7S486-, 7q31.1: FOXP2, MDFIC, TFEC, TES, No/NS No known genes Other 003 Autistic features, D7S522-) de novo, WBS inv-2 113,181,975-113,518,235 CAV2, CAV1 . . . to . . . IRF5, Yes/NS CCR5, CCRL2, Canadian Family (39989) speech-language de novo TNPO3, TSPAN33, SMO, CCR2 Described disorder 7q32.2: FAM40B, KIAA0828 No/S GYPE previously in Feuk (developmental 128,540,690-128,796,716 No/NS AMPH et al.³ verbal dyspraxia), Yes/S >50 genes dysmorphic features, Yes/NS MSC, TRPA1 mild developmental No/NS ANXAB delay, unable to Yes/S DOCK1 cough/sneeze/laugh spontaneously No/NS No known genes No/NS OR4K1, OR4N2, OR4M1, OR4K5, OR4Q3, OR4K2 No/S No known genes No/NS LOC283755, POTE15, OR4M2, OR4N4 No/NS No known genes No/NS 6 genes 19 SK0002- Simplex family 46, XX, inv(7)(p15.3; q22.1) 7p21.1: No known genes No/S No known genes Other 003 ASD, psychosis unknown 18,284,397-18,302,387 Non Canadian- (50002) 7q22.3: SPRK2 No/S No known genes Family 104,360,659-104,549,945 Yes/S LOC283755, POTE15, OR4M2, OR4N4 20 SK0211- Simplex family 46, XX, inv(7)(q22q34)mat 7q21.3: No known genes No/NS 10 genes Other 003 ASD, mild elevation inherited 96,943,657-96,985,663 Non Canadian (58892) of lactate 7q34: 140,920,721-140,958,207 TAS2R4, TAS2R5 No/NS No known genes Family Mother and unaffected twin sister have the same karyotype; 7q34 breakpoint overlaps with a ASD translocation patient 21 SK0040- Multiplex family 46, XY, t(7; 8)(p15; q22), t 7p15.3: No known genes No/S No known genes Other 003 ASD, ADHD, severe (10; 11)(q26; q23) 21,825,126-21,869,196 Non-Canadian (55449) anxiety attacks, unknown 8q22.2: STK3 No/S CTNNA3 Family seizures, difficulties 99,652,299-99,823,618 No/NS No know genes Unaffected sister with fine and gross 10q26: Multiple genes No/NS OR4K2, OR4N2, with normal motor skills 127,985,179-131,365,091 OR4K1, OR4K5 female karyotype, No/NS No known genes has difficulties in 11q23: Multiple genes No/S LOC283755, some muscles, 109,979,883-111,597,476 POTE15, difficulties with OR4M2, OR4N4 fine and gross No/NS PRAME, SUHW2, motor skills, SUHW1, GGTL4 severe anxiety No/S CTA, LRP5L attacks, not able to relate to peers and is affected by noise 22 SK0145- Simplex family 46, XX, t(7; 11)(q31; q25)mat 7q31.2: No known genes Yes/NS 8 genes Other 003 ASD inherited 114,573,150-114,611,613 Yes/NS No known genes Canadian Family (67955) 11q25: No known genes Yes/NS No known genes Apparently 133,882,647-134,001,155 Yes/NS 28 genes unaffected mother Yes/NS LRRC16 has the same No/NS No known genes 7q31.2 and 11q25 Yes/NS MSC breakpoints No/S PTCHD3 No/NS No known genes No/NS No known genes Yes/NS 9 genes Yes/NS 18 genes 23 SK0031- Simplex family 46, XY, t(7; 13)(q31.3; q21) mat 7q31.2: ST7 Yes/NS No known genes Other 003 ASD, very little inherited 116,270,156-116,458,896 No/NS HLA-A Non Canadian (68160L) language, global 13q21.1: No known genes No/NS No known genes Family developmental delays 54,559,087-54,739,454 Yes/S 8 genes No/S LOC283755, POTE15, OR4M2, OR4N4 No/NS 6 genes No/S CTA-246H3.1, LRP5L 24 SK0073- Simplex family 47, XX, idic(15)q13) 15q13: 28,918,525-31,848,963 LOC400968, LOC283755, Yes/NS 6 genes SK 003 ASD, developmental de novo POTE15, OR4M2, Yes/NS 7 genes Described (57283L) delay, delayed OR4N4 . . . to . . . Yes/NS 12 genes previously in expressive and ARHGAP11A, c15orf45, Yes/NS CASP3, Kwasnicka- receptive language GREM1, RYR3 CCDC111, Crawford et al.⁴ MLF1IP, ACSL1 Yes/S No known genes Yes/NS No known genes No/NS No known genes Yes/S >50 genes No/NS >20 genes No/NS >20 genes 25 SK0218- Multiplex family 46, XX, del(18)(q21) 18q21.32: See CNV Yes/S CACNA2D4, SK 003 ASD, cleft palate, de novo 55,690,398-55,884,029 ADIPOR2, As noted in the (60340) club feet, mild-facial LRTM2 Autism hypoplasia, heart No/S LOC283755, Chromosome defect POTE15, Rearrangment OR4M2, OR4N4 Database there No/NS KIAA1267 are 5 addition Yes/S >50 genes reported cases of No/NS KIR3DP1, abnormalities KIR2DL1, involving 18q; KIR3DL1, Sibling has a KIR2DL4, normal 46, XY KIR2DS4 karyotype also is Yes/NS RIN2 affected with autism and has oromotor difficulties. 26 SK0215- Simplex family 46, XY, t(19; 21)(p13.2; q22.12) 19p13.2: EVI5L, FLJ22184, LRRC8E, Yes/S FLJ35409, DPYD Other 006 ASD inherited 7,804,294-7,896,711 MAP2K7, SNAPC2, CTXN1 Canadian Family (58449) 21q22.12: No known genes Yes/NS FAM27L Patient has an 36,091,999-36,191,098 unaffected sister with the same karyotype 27 SK0136- Simplex family 46, X, der(Y)t(Y; 15) (q12; p11.2) pat Not available No/NS No known genes SK 003 ASD inherited No/NS No known genes (51253) No/NS No known genes No/NS PTCHD3 No/NS LOC283755 No/NS PCSK6, TARSL2, TM2D3, OR4F6 28 SK0243- Simplex Family 46, XY, del(15)(q23q24.2) See CNV See CNV No/NS No known genes SK 003 ASD de novo No/NS No known genes (67941) No/S KNG1, EIF4A2 No/NS No known genes No/NS No known genes No/NS No known genes No/NS MRGPRX1 Yes/S 55 genes No/NS No known genes No/NS No known genes 29 SK0245- Simplex Family 46, XY, trp(15)(q11.2q13) See CNV See CNV No/NS No known genes SK 005 ASD, epicanthal de novo No/NS No known genes (68517) folds, drooping eyes No/NS TARP No/NS MRGPRX1 No/S 6 genes No/NS No known genes Yes/S >50 genes No/S EMR4, FLG25758, MBD3L2, ZF557 30 NA0097- Simplex Family 46, XX, t(11; 12)(q23.3; p13.3) 11q23: not Yes/S >50 genes NFLD 000 ASD unknown available No/NS No known genes (82361L) No/S DDX11, OVOS2 12p13.32-p13.31: Multiple genes No/NS No known genes 4,341,718-7,918,138 Yes/S 21 genes 31 SK0300- Multiplex Family 46, X, inv(Y)(p11.2q11.2)pat Not available Yes/NS SORCS2 SK 003 ASD, NF1 inherited No/S ZDHHC11 (77447) Yes/S No known genes No/S No known genes Yes/S OR10A2, OR10A4, OR2D2, OR2D3 No/NS 6 genes No/S LOC283755, POTE15, OR4M2, OR4N4 Yes/S TRPM7, USP50 No/S ZNF630, SSX6 32 SK0094- Multiplex Family 46, XX, ins(21; ?)(p11.2; ?) Not available Yes/NS MTERF, AKAP9, SK 005 ASD unknown CYP51A1, (49304) LOC401387 No/NS KIAA1958, C9orf80 No/NS No known genes No/NS No known genes Yes/NS No known genes

Affymetrix GeneChip Human Mapping 500K Array Set

For each sample, approximately 500,000 SNPs were genotyped using the combined two-chip Nspl and Styl GeneChip® Human Mapping Commercial or Early Access Arrays (Affymetrix, Inc., Santa Clara, Calif.) according to the manufacturer's instructions and as described previously (Kennedy et al. 2003 Nat Biotechnol. 21:1233-7, the contents of which are incorporated herein by reference). Briefly, 250 ng of genomic DNA was digested with Nspl and Styl restriction enzyme (New England Biolabs, Boston, Mass.), ligated to an adaptor and amplified by PCR. The PCR products were then fragmented with DNaseI to a size range of 250 bp to 2,000 bp, labelled, and hybridized to the array. After hybridization, arrays were washed on the Affymetrix fluidics stations, stained, and scanned using the Gene Chip Scanner 3000 7G and Gene Chip Operating System. Data has been submitted to the Gene Expression Omnibus database (accession GSE9222). Karyotypes were generated using standard clinical diagnostic protocols.

Characterization of Copy Number Variation

Nspl and Styl array scans were analyzed for copy number variation using a combination of DNA Chip Analyzer (dChip) (Li and Wong 2001 Genome Biology 2: 0032.1-0032.11), Copy Number Analysis for GeneChip (CNAG) (Nannya 2005 Cancer Res. 65:6071-9) and Genotyping Microarray based CNV Analysis (GEMCA) (Komura 2006 Genome Res. 16:1575-84). Each of these references is incorporated herein by reference.

Analysis with dChip (www.dchip.org) was performed as previously described (Zhao et al 2005 Cancer Res. 65:5561-70) in batches of ˜100 probands. Briefly, array scans were normalized at the probe intensity level with an invariant set normalization method. After normalization, a signal value was calculated for each SNP using a model-based (PM/MM) method. In this approach, image artifacts were identified and eliminated by an outlier detection algorithm. For both sets of arrays, the resulting signal values were averaged across all samples for each SNP to obtain the mean signal of a diploid genome. From the raw copy numbers, the inferred copy number at each SNP was estimated using a Hidden Markov Model (HMM).

For analyses with CNAG version 2.0 (www.genome.umin.jp), the reference pool was set to include all samples and performed an automatic batch pair-wise analysis using sex-matched controls. Test samples were compared to all samples within the reference pool and matched based on signal intensity standard deviations. The scan intensities for each ‘test’ sample were compared to the average intensities of the reference samples (typically the average of 5-12 samples) and used to calculate raw copy number changes. Underlying copy number changes were then inferred using a Hidden Markov Model (HMM) built into CNAG.

GEMCA analysis was performed essentially as described (Komura et al. Genome Res 2006; 16 (12):1575-84) with the exception that two designated DNA samples (NA10851 and NA15510) were used as references for pair-wise comparison to all proband experiments. These results were further filtered by only including those CNVs that were common to both pair-wise experiments.

CNVs were merged if they were detected in the same individual by more than one algorithm using the outside probe boundaries.

Controls and Autism Chromosome Rearrangement Database (ACRD)

Control samples consisted of (i) CNVs observed in 500 Europeans from the from the German PopGen project (Krawczak et al. Community Genet 2006; 9 (1):55-61), and CNVs found in a cohort of 1000 Caucasian non-disease controls from the Ontario population (ref. 24). The ACRD that had 834 putative CNVs or breakpoints mapped to the genome was established. A CNV was considered ASD-specific if it was >10 kb, contained at least three probes and at least 20% of its total length was unique when compared to controls.

CNV Validation Experiments and Balance Rearrangement Breakpoint Mapping

PCR validation of CNV calls was performed using Quantitative Multiplex PCR of short fluorescent fragments (QMPSF) (Redon et al. Nature. 444:444-54) or SYBR-Green 1 based real-time quantitative PCR (qPCR) using controls at the ACCN1, CFTR or FOXP2 loci (PMID: 14552656). For both methods, primers were designed using the program PRIMER3 (http://frodo.wi.mit.edu/). Balanced rearrangements were mapped primarily using FISH (Nannya et al. Cancer Res 2005; 65 (14):6071-9). The microdel program (Komura et al., ibid) was used to score CNV losses.

For QMPSF, short genomic sequences (140-220 bp) within putative CNVs were PCR amplified using dye-labelled primers corresponding to unique sequences. Each reaction also included co-amplified control amplicons corresponding to either ACCN1 or CFTR located at 17q11.2 and 7q31.2, respectively. Briefly, 40 ng of genomic DNA was amplified by PCR in a final volume of 25 μl using AmpliTaq® DNA polymerase (manufactured for Applied Biosystems by Roche Molecular Systems, Inc.) After an initial step of denaturation at 95° C. for 5 minutes conditions were as follows: 25 PCR cycles of 94° C. for 30 seconds, annealing at 60° C. for 45 seconds, and extension at 72° C. for 30 seconds. A final extension step at 72° C. for 15 minutes followed. QMPSF amplicons were separated on an ABI 3730xl DNA Analyzer (Applied. Biosystems, Foster City, Calif.), and analyzed using ABI GeneMapper® software version 3.7 (Applied Biosystems). After adjustment of control amplicons to the same heights, the QMPSF pattern generated from test DNA was superimposed to that of the control DNA. For each putative CNV locus, the copy number ratio was determined by dividing the normalized peak height obtained from the test DNA by that of the control DNA. Peak ratios of >1.4 and <0.7 were indicative of copy number gains and losses, respectively. At least two independent QMPSF assays were required for CNV confirmation.

SYBR Green I-based real-time qPCR amplification was performed using a Mx3005P quantitative PCR system (Stratagene, La Jolla, USA). Non-fluorescent primers were designed to amplify short genomic fragments (<140 bp) in putative CNV loci. Each assay also included amplification of a control amplicon corresponding to FOXP2 at 7q31.1 for comparison. After optimization of primer sets with control genomic DNA using ‘Brilliant® SYBR® Green QPCR Master Mix’ (Stratagene), test samples were assayed in 15 μl reaction mixtures in 96-well plates containing: 7.5 μl of reaction mix, 1.8 μl of primer, 6.0 ng of genomic DNA at 1.2 ng/μl, 0.225 μl of reference dye with 1:500 dilution, and 0.475 μl of water. PCR conditions consisted of 10 minutes of polymerase activation at 95° C., followed by 40 cycles of: 95° C. for 15 seconds and a single step at 60° C. for 1 minute for annealing and elongation. These steps were then followed by a final cycle of 95° C. for 1 minute, 55° C. for 30 seconds, and 95° C. for 30 seconds. Standard curve quantification was analyzed by MxPro-Mx3005P software (version 3.20 Build 340) to calculate copy number changes. Coefficient of variation (CV) was calculated on all sample Ct values to remove possible outlier when CV was greater than 1%. The average quantity of the putative CNV locus was divided by the average quantity of the control amplicon on FOXP2. Ratios of >1.4 and <0.7 were indicative of copy number gains and losses, respectively. Each putative CNV locus had at least two independent assays.

Results Structural Variation Characteristics in ASD Cases

A total of 426 ASD index cases were tested for CNV content including 394 typical idiopathic cases and 32 others that were enrolled based on prior knowledge of having a cytogenetic abnormality. The Affymetrix 500k SNP array was used because it provided the highest resolution screen available for both SNP genotype and CNV data. Using the SNPs, the ancestry of each sample was categorized (to guide selection of controls). Backgrounds of the samples were found to be: 90.3%, 4.5%, 4.5%, and 0.7%, European, European/mixed, Asian, or Yoruban, respectively.

To maximize CNV discovery, three calling algorithms were used as described above (see FIG. 1) and common results between them were merged to identify a ‘full’ dataset of 3389 independent CNVs (˜8 CNVs per genome, mean size 390 kb) (see Table 4 below). To minimize potential false positives, a second dataset was generated whereby a CNV needed to be detected by two or more algorithms and/or on both the NspI or StyI microarrays (Pinto et al. Hum Mol Genet 2007; 16 Spec No 2:R168-73).

This ‘stringent’ dataset contained 1312 CNVs (˜3 CNVs per genome, mean size 603 kb). Using q-PCR, 48% (12/26) and 96% (48/50) of random CNVs were validated in the full and stringent collections, respectively.

TABLE 4 Summary of CNV in ASD and Controls POPGEN CONTROLS AUTISM PROBANDS All CNVs All CNVs Autism Specific¹ Full Stringent² Full Stringent² Full Stringent² #samples 500 500 426 426 426 426 #CNVs 3695 1558 3389 1312 888 276 CNV/Genome³ 7.4 3.1 8.0 3.1 2.1 0.65 Mean/Median Size 315/151 470/224 390/162 603/219 518/121 1082/194  (kb) % Gain/Loss    59/41%    70/30%    58/42%    62/38%    61/39%    57/43% Overlapping 3005/333 1226/142 2728/277 980/94 397/122 30/13 CNV/Loci (%)⁴ (81%) (78%) (80%) (74%) (44%) (11%) >1Mb CNV (%) 343 250 339 212 63 32  (9%) (16%) (10%) (16%)  (7%) (12%) ¹Not seen in controls. ²Stringent dataset as called by >1 algorithms or arrays. Analysis with dChip was performed in batches of ~100 probands. For CNAG version 2.0, the reference pool was set to include all samples and performed an automatic batch pairwise analysis using sex-matched controls. For GEMCA two designated DNA samples (NA10851 and NA15510) were used as references for pairwise comparison to all proband experiments. These results were further filtered by only including those CNVs that werecommon to both pairwise experiments. In all instances CNVs were merged if they were detected in the same individual by more than one algorithm using the outside probe boundaries. ³CNV/genome breakdown by algorithm: dChip Merged (3.0/genome), CNAG Merged (5.6/genome), GEMCA (5.5/genome). Validation experiments using q-PCR and FISH are described in the text. Another form of validation comes from examining the trios where we can demonstrate inheritance in 48 (maternal is 25, paternal is 23) of the autism-specific stringent dataset. Also from the trios, 148 confirmed regions (inheritance assignment) in the stringent dataset that overlap with controls (maternalis 65, paternal is 83). ⁴Represents the total number of overlapping and/or recurrent CNVs, the number of overlapping/CNV loci, and the percentage of overlapping CNVs, out of the total dataset.

Five hundred European control samples were examined for their CNV content and similar numbers of CNVs (3695 in the full and 1558 in the stringent dataset) were found to those in the ASD cases (Table 4). This suggested germ-line chromosome instability was not a significant contributing mechanism. The ASD CNVs were then compared against the 500 European/Caucasian controls and the Database of Genomic Variants (a repository of structural variation in ‘non-disease’ populations) (Iafrate et al. Nat Genet 2004; 36 (9):949-51) to establish autism-specific CNV datasets. The subsequent analysis then focused on the 276 CNVs in the stringent autism-specific category, which mapped across all 23 chromosomes (FIG. 2), details of which are found in Table 3, below. Additional ASD-relevant CNV data is also found in the other categories in Table 5 (discussed below).

TABLE 3 FAM ID (DNA) Sex Type Chr start stop size CNV CNV Category SK0215-006 (58449) M CHR 1 97,271,600 98,364,100 1,092,500 loss CNVs confirmed de novo SK0152-003 (41548L) M CHR 3 15,125,800 16,535,400 1,409,600 loss CNVs confirmed de novo SK0181-003 (52191) M CHR 3 65,286,300 70,633,200 5,346,900 loss CNVs confirmed de novo SK0205-004 (56242) F CHR 5 81,949 13,882,933 13,800,984 loss CNVs confirmed de novo SK0152-003 (41548L) M CHR 5 9,275,811 12,705,200 3,429,389 loss CNVs confirmed de novo SK0083-003 (50800L) M CHR 7 108,200,381 119,223,887 11,023,507 loss CNVs confirmed de novo SK0131-003 (39989) F CHR 7 113,335,000 128,821,721 15,486,722 loss CNVs confirmed de novo SK0262-003 (68609) M SPX 8 710,491 1,501,580 791,089 gain CNVs confirmed de novo SK0152-003 (41548L) M CHR 12 40,584,198 41,007,040 422,842 loss CNVs confirmed de novo MM0278-003 (57788) M SPX 12 114,170,000 132,388,000 18,218,001 gain CNVs confirmed de novo SK0243-003 (67941) M CHR 15 69,601,300 73,890,800 4,289,500 loss CNVs confirmed de novo NA0067-000 (65344L) M SPX 16 87,800,593 88,066,260 265,668 loss CNVs confirmed de novo SK0218-003 (60340) F CHR 18 55,756,601 76,115,600 20,358,999 loss CNVs confirmed de novo MM0109-003 (46486) F SPX 20 60,949,339 62,377,000 1,427,662 gain CNVs confirmed de novo SK0244-003 (69183) M SPX 21 42,974,148 43,328,084 353,936 gain CNVs confirmed de novo NA0039-000 (69736) F CHR 22 46,277,400 49,509,100 3,231,700 loss CNVs confirmed de novo MM0109-003 (46486) F SPX 22 49,243,247 49,519,949 276,703 loss CNVs confirmed de novo NA0097-000 (82361L) F CHR X 34,419 5,859,730 5,825,312 loss CNVs confirmed de novo SK0306-004 (78681) F SPX X 48,073,600 52,716,966 4,643,367 gain CNVs confirmed de novo SK0147-003 (47544L) F SPX 2 114,855,796 115,334,166 478,371 loss CNVs Recurrent/Overlapping SK0167-003 (60966L) F MPX 2 114,855,796 115,334,166 478,371 gain CNVs Recurrent/Overlapping SK0288-003 (75420) F SPX-MZ 2 115,141,880 115,247,000 105,121 gain CNVs Recurrent/Overlapping NA0030-000 (55240) M SPX 2 186,674,000 186,786,323 112,324 loss CNVs Recurrent/Overlapping SK0306-004 (78681) F SPX 2 186,674,000 186,771,130 97,131 loss CNVs Recurrent/Overlapping MM0220-003 (61180L) M MPX 6 118,799,000 119,117,000 318,001 gain CNVs Recurrent/Overlapping NA0025-000 (60490) M SPX 6 118,823,011 119,117,000 293,990 gain CNVs Recurrent/Overlapping SK0190-003 (54742) M SPX 7 152,698,000 154,478,000 1,780,000 gain CNVs Recurrent/Overlapping SK0115-003 (40555) M SPX 7 153,098,000 153,372,000 274,001 gain CNVs Recurrent/Overlapping SK0058-003 (59963) M MPX 7 153,539,745 153,556,533 16,789 gain CNVs Recurrent/Overlapping SK0143-003 (36812) M SPX 8 53,481,200 53,766,400 285,201 gain CNVs Recurrent/Overlapping MM0236-004 (46475) M MPX 8 53,724,445 53,996,124 271,680 gain CNVs Recurrent/Overlapping SK0270-003 (71341) M SPX 9 7,725,280 7,764,180 38,900 loss CNVs Recurrent/Overlapping MM0103-003 (42387) M MPX 9 7,725,283 7,760,233 34,951 loss CNVs Recurrent/Overlapping MM0272-003 (45563) M MPX 11 40,285,800 40,548,738 262,939 loss CNVs Recurrent/Overlapping SK0167-003 (60966L) F MPX 11 40,417,554 40,610,400 192,847 loss CNVs Recurrent/Overlapping SK0023-003 (58096) M SPX 13 66,470,851 66,660,289 189,438 gain CNVs Recurrent/Overlapping MM0299-003 (51674) F MPX 13 66,487,899 66,660,300 172,402 gain CNVs Recurrent/Overlapping MM0109-003 (46486) F SPX 16 21,441,805 22,688,093 1,246,289 gain CNVs Recurrent/Overlapping MM0289-003 (42267) F MPX 16 21,808,808 22,611,363 802,556 loss CNVs Recurrent/Overlapping MM0088-003 (45562) F MPX 16 29,559,989 30,235,818 675,830 loss CNVs Recurrent/Overlapping NA0133-000 (78119L) F SPX 16 29,559,989 30,085,308 525,320 gain CNVs Recurrent/Overlapping SK0091-004 (46407) F MPX 22 17,265,500 21,546,762 4,281,262 gain CNVs Recurrent/Overlapping SK0323-003 (80022) M MPX 22 18,683,900 19,427,000 743,101 gain CNVs Recurrent/Overlapping SK0123-004 (60536L) M MPX 22 47,717,300 48,318,828 601,528 gain CNVs Recurrent/Overlapping MM0102-003 (47598) M MPX 22 48,152,289 48,232,669 80,380 loss CNVs Recurrent/Overlapping NA0002-000 (52026) M SPX 7 153,585,000 153,651,462 66,463 loss CNVs Recurrent/Overlapping/ CNVs confirmed de novo SK0073-003 (57283L) F CHR 15 18,376,200 30,298,800 11,922,600 gain CNVs Recurrent/Overlapping/ CNVs confirmed de novo SK0245-005 (68517) M CHR 15 18,427,100 30,298,847 11,871,747 gain CNVs Recurrent/Overlapping/ CNVs confirmed de novo SK0119-003 (35190) M MPX 22 17,014,900 19,786,200 2,771,300 loss CNVs Recurrent/Overlapping/ CNVs confirmed de novo SK0297-003 (76066) M SPX-MZ 22 17,265,500 21,546,762 4,281,263 gain CNVs Recurrent/Overlapping/ CNVs confirmed de novo MM0109-003 (46486) F SPX 17 40,555,289 41,089,766 534,478 loss CNVs that are Singletons MM0240-003 (43743) F MPX 17 40,555,289 41,128,323 573,035 loss CNVs that are Singletons NA0074-000 (63358) M SPX 1 41,463,611 41,924,314 460,704 gain CNVs that are Singletons SK0036-003 (29186) F SPX 1 57,936,233 58,514,629 578,396 gain CNVs that are Singletons MM0236-004 (46475) M MPX 1 60,369,200 61,426,300 1,057,101 gain CNVs that are Singletons MM0020-004 (47838) M MPX 1 65,649,086 65,713,423 64,338 gain CNVs that are Singletons NA0076-000 (63624) M SPX 1 91,930,266 92,330,344 400,078 gain CNVs that are Singletons SK0174-003 (64379L) M SPX 1 108,046,000 108,246,283 200,284 loss CNVs that are Singletons SK0283-003 (72309) F CHR 1 148,095,537 149,547,463 1,451,926 gain CNVs that are Singletons MM0011-003 (60566L) M MPX 1 165,908,677 166,028,402 119,726 loss CNVs that are Singletons SK0132-003 (30661) M MPX 1 186,673,899 186,716,570 42,672 loss CNVs that are Singletons NA0109-000 (72873) M SPX 1 212,037,558 212,471,000 433,443 loss CNVs that are Singletons SK0183-004 (52217) M SPX 1 238,633,145 239,606,926 973,781 loss CNVs that are Singletons MM0219-003 (46823) M MPX 2 34,155,700 34,253,221 97,522 loss CNVs that are Singletons MM0295-003 (46488) M MPX 2 34,662,196 34,780,515 118,320 loss CNVs that are Singletons NA0083-000 (66104L) M SPX 2 34,858,330 34,937,455 79,125 loss CNVs that are Singletons SK0270-003 (71341) M SPX 2 39,992,374 40,053,300 60,926 loss CNVs that are Singletons NA0055-000 (59448) M SPX 2 41,958,200 42,088,448 130,249 loss CNVs that are Singletons SK0301-003 (77203) M MPX 2 52,856,046 52,969,575 113,530 loss CNVs that are Singletons NA0027-000 (60421L) M MPX 2 121,623,000 121,684,915 61,915 loss CNVs that are Singletons NA0057-000 (59537) M SPX 2 125,496,832 125,890,571 393,740 loss CNVs that are Singletons MM0176-003 (62118L) M MPX 2 135,358,000 135,471,070 113,071 loss CNVs that are Singletons SK0225-003 (60921) M SPX 2 155,849,451 155,988,560 139,109 loss CNVs that are Singletons SK0192-003 (54877) M SPX 2 181,771,621 181,944,065 172,445 loss CNVs that are Singletons NA0007-000 (50611) M SPX 2 195,170,000 195,217,247 47,248 gain CNVs that are Singletons SK0283-003 (72309) F CHR 3 5,365,506 5,409,964 44,458 loss CNVs that are Singletons MM0210-004 (47376) M MPX 3 7,957,390 8,250,541 293,151 gain CNVs that are Singletons NA0044-000 (57097) M SPX 3 35,613,300 35,928,200 314,901 gain CNVs that are Singletons SK0021-008 (51504) M MPX 3 36,110,965 36,215,909 104,945 loss CNVs that are Singletons MM0154-003 (56678L) F MPX 3 50,089,500 50,199,200 109,701 gain CNVs that are Singletons SK0152-003 (41548L) M CHR 3 78,902,000 78,957,000 55,000 gain CNVs that are Singletons NA0044-000 (57097) M SPX 3 82,866,400 84,544,763 1,678,364 gain CNVs that are Singletons SK0023-003 (58096) M SPX 3 99,400,957 99,484,400 83,443 gain CNVs that are Singletons NA0018-000 (72622) M SPX 3 117,838,700 117,937,000 98,301 gain CNVs that are Singletons NA0003-000 (48474) M SPX 3 124,386,373 124,456,000 69,628 gain CNVs that are Singletons NA0090-000 (65410) M SPX 3 183,837,706 183,940,069 102,364 gain CNVs that are Singletons NA0044-000 (57097) M SPX 4 55,718,164 55,811,710 93,547 loss CNVs that are Singletons NA0016-000 (51524L) F SPX 4 114,333,509 114,416,051 82,542 loss CNVs that are Singletons SK0012-003 (58468L) M SPX 4 152,993,000 153,381,007 388,008 gain CNVs that are Singletons SK0103-005 (42258) M SPX 4 157,615,000 157,683,000 68,000 gain CNVs that are Singletons NA0037-000 (69812) M SPX 4 179,692,000 179,865,679 173,680 gain CNVs that are Singletons MM0299-003 (51674) F MPX 4 181,968,784 182,095,665 126,882 loss CNVs that are Singletons SK0266-003 (68257) M SPX 4 183,466,000 183,517,000 51,000 loss CNVs that are Singletons SK0002-003 (50002) F CHR 5 14,940,400 15,179,500 239,100 gain CNVs that are Singletons NA0078-000 (63727) M MPX 5 25,125,371 25,450,672 325,302 gain CNVs that are Singletons NA0076-000 (63624) M SPX 5 37,409,881 37,778,834 368,953 gain CNVs that are Singletons SK0335-003 (72815) F CHR 5 38,534,384 38,807,002 272,619 loss CNVs that are Singletons MM0143-004 (47386) M MPX 5 110,440,484 110,471,180 30,697 gain CNVs that are Singletons NA0023-000 (60504L) F SPX 5 113,104,916 113,178,000 73,084 loss CNVs that are Singletons SK0118-003 (52027) M SPX 5 122,834,399 123,029,036 194,638 loss CNVs that are Singletons SK0077-003 (48226) M SPX 5 128,968,799 129,433,000 464,201 gain CNVs that are Singletons SK0300-003 (77447) M CHR 6 4,200,904 4,416,471 215,568 loss CNVs that are Singletons MM0212-004 (62223L) F MPX 6 17,505,095 17,703,208 198,114 gain CNVs that are Singletons MM0300-003 (47836) F MPX 6 27,827,354 28,119,631 292,278 gain CNVs that are Singletons MM0225-004 (60826) M MPX 6 69,929,900 70,278,043 348,144 gain CNVs that are Singletons SK0217-003 (59279) M SPX 6 112,679,982 112,776,094 96,112 gain CNVs that are Singletons SK0326-003 (81155) M SPX 6 137,930,847 138,011,644 80,798 gain CNVs that are Singletons MM0088-003 (45562) F MPX 7 2,922,139 2,964,895 42,757 loss CNVs that are Singletons NA0147-000 (77123L) M SPX 7 3,946,854 4,002,686 55,833 loss CNVs that are Singletons SK0049-004 (59987L) M MPX 7 11,526,500 11,560,300 33,800 gain CNVs that are Singletons SK0132-003 (30661) M MPX 7 20,242,925 20,345,800 102,876 gain CNVs that are Singletons NA0145-000 (82058L) M SPX 7 47,742,927 48,775,200 1,032,274 loss CNVs that are Singletons SK0119-003 (35190) M MPX 8 17,706,313 17,738,524 32,211 loss CNVs that are Singletons SK0262-003 (68609) M SPX 8 18,623,000 19,442,500 819,500 gain CNVs that are Singletons SK0077-003 (48226) M SPX 8 42,971,601 43,820,300 848,699 gain CNVs that are Singletons SK0294-003 (76222) M SPX 8 73,762,894 73,798,241 35,348 gain CNVs that are Singletons SK0076-003 (38712) F SPX 8 83,989,256 84,141,278 152,022 gain CNVs that are Singletons MM0241-004 (45547) M MPX 8 87,230,811 87,498,988 268,178 gain CNVs that are Singletons MM0210-004 (47376) M MPX 8 104,166,572 104,947,190 780,618 gain CNVs that are Singletons SK0194-003 (55078) M SPX 8 123,539,127 123,644,422 105,296 loss CNVs that are Singletons SK0292-003 (75896) F MPX 8 130,467,000 130,529,193 62,194 loss CNVs that are Singletons MM0007-003 (59978) M MPX 9 5,099,530 5,235,490 135,961 gain CNVs that are Singletons MM0711-003 (63583L) M MPX 9 16,092,066 16,379,100 287,035 gain CNVs that are Singletons SK0015-003 (49932) M MPX 9 19,284,100 19,511,500 227,400 gain CNVs that are Singletons SK0015-003 (49932) M MPX 9 19,702,200 24,674,100 4,971,900 loss CNVs that are Singletons SK0278-003 (74431) M SPX 9 22,626,541 22,747,714 121,174 loss CNVs that are Singletons SK0148-005 (41350) F SPX 9 24,607,036 24,682,114 75,078 loss CNVs that are Singletons MM0020-004 (47838) M MPX 9 25,439,100 25,535,000 95,901 loss CNVs that are Singletons NA0105-000 (72085) M SPX 9 33,054,336 33,294,800 240,465 gain CNVs that are Singletons NA0147-000 (77123L) M SPX 9 84,957,060 85,054,672 97,613 loss CNVs that are Singletons SK0045-003 (58937) M MPX 9 109,446,000 109,837,000 391,000 gain CNVs that are Singletons MM0117-003 (59983) M MPX 10 2,313,505 2,407,102 93,598 loss CNVs that are Singletons MM0225-004 (60826) M MPX 10 4,976,040 5,124,511 148,472 gain CNVs that are Singletons MM1086-004 (76285) M MPX 10 31,256,118 31,604,509 348,392 loss CNVs that are Singletons MM0068-003 (60836) M MPX 10 68,139,200 68,246,027 106,828 loss CNVs that are Singletons NA0037-000 (69812) M SPX 10 104,641,000 104,786,777 145,778 loss CNVs that are Singletons SK0300-003 (77447) M CHR 11 6,845,440 6,899,830 54,391 loss CNVs that are Singletons SK0322-003 (79950) M SPX 11 33,159,190 33,462,070 302,881 gain CNVs that are Singletons MM0305-003 (47607) M MPX 11 68,053,777 68,204,900 151,123 gain CNVs that are Singletons NA0032-000 (55186) M SPX 11 76,114,600 76,140,500 25,900 gain CNVs that are Singletons MM0212-004 (62223L) F MPX 11 99,148,202 99,289,243 141,042 loss CNVs that are Singletons SK0167-003 (60966L) F MPX 11 101,131,785 101,246,901 115,117 loss CNVs that are Singletons MM0112-005 (46736) M MPX 11 116,789,980 116,855,347 65,368 gain CNVs that are Singletons MM0240-003 (43743) F MPX 11 117,452,000 117,539,000 87,001 gain CNVs that are Singletons SK0255-003 (68785) M SPX 11 124,303,460 124,719,976 416,517 gain CNVs that are Singletons NA0065-000 (62798L) M SPX 11 125,639,908 126,102,027 462,120 gain CNVs that are Singletons NA0172-000 (80993L) M SPX 12 3,727,911 3,879,230 151,320 loss CNVs that are Singletons SK0059-003 (29224) M SPX 12 10,431,082 10,445,300 14,218 gain CNVs that are Singletons SK0326-003 (81155) M SPX 12 46,170,200 46,365,774 195,575 gain CNVs that are Singletons SK0110-003 (24626) M SPX 12 50,520,400 50,573,516 53,116 gain CNVs that are Singletons NA0071-000 (64719L) F SPX 12 57,408,270 58,532,356 1,124,087 gain CNVs that are Singletons SK0305-003 (78621) F SPX 12 77,239,265 77,364,400 125,136 loss CNVs that are Singletons SK0301-003 (77203) M MPX 12 83,388,935 83,428,800 39,866 gain CNVs that are Singletons NA0093-000 (66999) M SPX 12 96,496,784 96,568,500 71,716 loss CNVs that are Singletons MM0711-003 (63583L) M MPX 12 96,576,486 96,639,686 63,201 loss CNVs that are Singletons SK0292-003 (75896) F MPX 12 101,568,000 101,586,000 18,001 gain CNVs that are Singletons NA0109-000 (72873) M SPX 12 110,646,607 110,800,000 153,394 gain CNVs that are Singletons MM0210-004 (47376) M MPX 12 125,446,000 125,757,000 311,000 gain CNVs that are Singletons SK0079-003 (48388) M MPX 13 17,960,300 18,492,994 532,694 gain CNVs that are Singletons NA0028-000 (58891L) M SPX 13 62,915,912 62,977,748 61,837 loss CNVs that are Singletons SK0326-003 (81155) M SPX 13 89,726,966 90,134,219 407,254 gain CNVs that are Singletons NA0048-000 (58569) M SPX 13 93,288,520 93,344,600 56,081 gain CNVs that are Singletons SK0326-003 (81155) M SPX 13 93,497,400 93,732,931 235,532 gain CNVs that are Singletons SK0254-003 (68687) M SPX 13 105,172,000 105,357,000 185,000 gain CNVs that are Singletons SK0121-003 (41288) M SPX 14 76,007,842 76,924,400 916,558 gain CNVs that are Singletons SK0031-003 (68160L) M CHR 14 99,015,100 99,787,500 772,400 gain CNVs that are Singletons SK0300-003 (77447) M CHR 15 48,583,127 48,767,030 183,904 gain CNVs that are Singletons SK0326-003 (81155) M SPX 15 97,406,000 97,961,522 555,523 gain CNVs that are Singletons SK0281-003 (72934) M SPX 16 57,542,779 57,579,900 37,122 loss CNVs that are Singletons MM0310-005 (60951) M MPX 16 80,972,252 80,983,135 10,884 loss CNVs that are Singletons SK0203-004 (56040) M MPX 16 82,603,600 82,687,900 84,300 gain CNVs that are Singletons SK0085-004 (30422) M MPX 17 3,836,592 3,998,867 162,276 gain CNVs that are Singletons SK0298-003 (77697) M SPX 17 76,914,079 77,771,141 857,063 gain CNVs that are Singletons SK0328-003 (82302) M SPX 18 13,794,043 14,743,900 949,858 gain CNVs that are Singletons SK0303-003 (78391) F MPX 18 28,383,551 28,448,100 64,550 loss CNVs that are Singletons SK0014-003 (41606) M SPX 18 52,531,252 53,165,421 634,169 gain CNVs that are Singletons SK0121-003 (41288) M SPX 19 33,693,363 33,762,805 69,442 loss CNVs that are Singletons NA0111-000 (73891) M SPX 19 57,836,600 58,246,200 409,601 gain CNVs that are Singletons NA0004-000 (47490) M SPX 19 58,634,965 58,958,584 323,620 gain CNVs that are Singletons NA0070-000 (64249L) F SPX 19 60,499,398 60,742,656 243,259 loss CNVs that are Singletons SK0047-003 (47173L) F SPX 19 61,910,800 62,644,900 734,100 loss CNVs that are Singletons NA0110-000 (72165) M SPX 19 63,050,356 63,193,800 143,445 loss CNVs that are Singletons SK0232-003 (59838) M MPX 19 63,483,000 63,771,100 288,100 gain CNVs that are Singletons MM0018-003 (59980) M MPX 20 11,319,093 11,424,900 105,808 loss CNVs that are Singletons SK0335-003 (72815) F CHR 20 14,955,730 15,011,214 55,485 loss CNVs that are Singletons SK0258-004 (67930) M SPX 20 45,468,000 45,673,300 205,300 gain CNVs that are Singletons MM0126-003 (54581) M MPX 21 22,839,570 22,938,377 98,808 loss CNVs that are Singletons SK0118-003 (52027) M SPX 21 28,060,406 28,250,400 189,995 loss CNVs that are Singletons SK0186-004 (52964) M SPX X 22,962,800 23,119,000 156,200 loss CNVs that are Singletons MM0087-003 (59962L) M MPX X 25,516,263 25,620,400 104,138 loss CNVs that are Singletons NA0100-000 (70601L) M SPX X 44,395,900 45,060,800 664,901 gain CNVs that are Singletons SK0087-003 (60692L) F MPX X 83,866,300 92,175,100 8,308,800 loss CNVs that are Singletons MM0020-004 (47838) M MPX X 87,452,050 87,595,200 143,151 gain CNVs that are Singletons SK0228-003 (62083) M SPX X 104,153,000 104,638,000 485,000 gain CNVs that are Singletons SK0088-003 (64798) M SPX X 114,042,922 114,215,435 172,513 gain CNVs that are Singletons MM0087-003 (59962L) M MPX X 130,406,000 130,695,499 289,500 gain CNVs that are Singletons NA0016-000 (51524L) F SPX X 140,600,370 140,907,495 307,125 gain CNVs that are Singletons SK0234-003 (64340) M MPX X 142,561,000 142,682,000 121,000 loss CNVs that are Singletons SK0320-003 (79449) M MPX X 143,059,574 143,399,300 339,727 gain CNVs that are Singletons SK0123-004 (60536L) M MPX X 147,974,000 148,479,449 505,449 gain CNVs that are Singletons SK0278-003 (74431) M SPX 1 188,543,244 188,935,335 392,092 gain CNVs that overlap the ACRD MM0149-003 (42382) M MPX 1 191,030,551 191,223,110 192,560 gain CNVs that overlap the ACRD SK0229-003 (62211) M SPX 1 242,451,000 243,113,489 662,489 gain CNVs that overlap the ACRD NA0016-000 (51524L) F SPX 1 243,172,012 243,301,056 129,044 gain CNVs that overlap the ACRD MM0063-003 (46687) F MPX 2 50,780,202 50,859,200 78,999 loss CNVs that overlap the ACRD SK0234-003 (64340) M MPX 2 54,171,783 54,345,700 173,917 gain CNVs that overlap the ACRD SK0188-003 (53664) M SPX 2 112,415,581 112,510,212 94,632 loss CNVs that overlap the ACRD MM0019-003 (42052) M MPX 2 201,286,000 201,317,066 31,067 loss CNVs that overlap the ACRD MM0296-003 (47829) M MPX 2 221,429,610 221,551,000 121,391 loss CNVs that overlap the ACRD NA0004-000 (47490) M SPX 2 235,797,267 236,239,000 441,734 gain CNVs that overlap the ACRD MM0068-003 (60836) M MPX 3 1,720,948 1,795,234 74,287 gain CNVs that overlap the ACRD NA0067-000 (65344L) M SPX 3 61,075,295 61,581,100 505,806 gain CNVs that overlap the ACRD MM0296-003 (47829) M MPX 4 328,851 542,862 214,012 gain CNVs that overlap the ACRD MM0228-004 (47602) M MPX 4 11,820,924 11,983,053 162,130 loss CNVs that overlap the ACRD NA0129-000 (77405) M SPX 4 38,109,899 38,349,444 239,546 gain CNVs that overlap the ACRD SK0188-003 (53664) M SPX 4 61,408,094 61,758,800 350,707 loss CNVs that overlap the ACRD SK0057-003 (40919) M SPX 4 74,105,700 74,464,300 358,600 gain CNVs that overlap the ACRD MM0176-003 (62118L) M MPX 4 91,220,121 91,309,602 89,482 loss CNVs that overlap the ACRD SK0012-003 (58468L) M SPX 4 162,387,402 163,362,655 975,254 gain CNVs that overlap the ACRD SK0012-003 (58468L) M SPX 4 173,324,616 174,954,056 1,629,441 gain CNVs that overlap the ACRD SK0166-003 (36773) M SPX 4 186,788,000 187,118,000 330,001 gain CNVs that overlap the ACRD SK0074-003 (60910L) M MPX 4 188,230,567 190,154,000 1,923,434 gain CNVs that overlap the ACRD SK0083-003 (50800L) M CHR 4 188,232,000 188,253,314 21,315 gain CNVs that overlap the ACRD MM0019-003 (42052) M MPX 4 190,172,765 191,306,043 1,133,279 gain CNVs that overlap the ACRD SK0188-003 (53664) M SPX 5 13,832,700 14,237,600 404,901 gain CNVs that overlap the ACRD NA0078-000 (63727) M MPX 5 79,336,190 79,613,516 277,327 loss CNVs that overlap the ACRD NA0145-000 (82058L) M SPX 5 89,445,869 90,172,900 727,032 gain CNVs that overlap the ACRD SK0167-003 (60966L) F MPX 5 120,343,925 120,474,000 130,076 gain CNVs that overlap the ACRD NA0019-000 (64122L) M SPX 5 120,964,000 121,095,213 131,214 gain CNVs that overlap the ACRD MM0215-004 (47095) M MPX 5 132,619,430 132,732,003 112,574 loss CNVs that overlap the ACRD SK0073-003 (57283L) F CHR 5 134,426,000 134,519,000 93,000 gain CNVs that overlap the ACRD SK0272-003 (70721) F SPX 6 77,622,920 77,673,932 51,012 loss CNVs that overlap the ACRD MM0225-004 (60826) M MPX 6 93,087,482 98,011,900 4,924,419 gain CNVs that overlap the ACRD SK0077-003 (48226) M SPX 6 95,461,800 95,581,304 119,504 loss CNVs that overlap the ACRD SK0087-003 (40450) M MPX 6 97,566,274 97,658,527 92,253 loss CNVs that overlap the ACRD SK0216-003 (58875) M SPX 6 153,519,631 153,791,029 271,398 gain CNVs that overlap the ACRD NA0061-000 (60383) M SPX 7 108,357,049 108,597,525 240,477 loss CNVs that overlap the ACRD SK0226-005 (61360) M SPX 7 118,462,717 118,679,189 216,473 loss CNVs that overlap the ACRD MM0218-004 (45553) M MPX 8 89,598,961 89,678,800 79,840 loss CNVs that overlap the ACRD SK0210-004 (57601) M MPX 9 28,577,800 29,218,800 641,000 loss CNVs that overlap the ACRD SK0273-003 (71182) M MPX 9 70,739,231 70,870,084 130,854 loss CNVs that overlap the ACRD SK0118-003 (52027) M SPX 9 111,652,000 112,212,452 560,453 gain CNVs that overlap the ACRD NA0066-000 (64119L) M SPX 9 116,528,784 116,612,329 83,546 loss CNVs that overlap the ACRD SK0102-004 (31899) M SPX 10 42,611,900 43,266,300 654,400 gain CNVs that overlap the ACRD SK0102-004 (31899) M SPX 10 44,988,900 45,468,800 479,900 gain CNVs that overlap the ACRD NA0109-000 (72873) M SPX 10 112,267,330 112,405,408 138,079 gain CNVs that overlap the ACRD SK0131-003 (39989) F CHR 10 128,501,014 128,592,091 91,078 gain CNVs that overlap the ACRD NA0138-000 (81816L) M SPX 10 133,285,000 133,604,999 320,000 gain CNVs that overlap the ACRD NA0113-000 (82366L) M SPX 11 9,984,119 10,667,800 683,682 loss CNVs that overlap the ACRD SK0218-003 (60340) F CHR 12 1,760,084 1,852,412 92,328 loss CNVs that overlap the ACRD NA0122-000 (76018L) F SPX 13 32,965,700 33,137,655 171,956 gain CNVs that overlap the ACRD NA0117-000 (73621) M SPX 13 42,511,458 42,599,200 87,743 gain CNVs that overlap the ACRD MM0154-003 (56678L) F MPX 13 54,651,953 55,025,229 373,277 gain CNVs that overlap the ACRD SK0328-003 (82302) M SPX 13 103,896,769 103,930,492 33,724 loss CNVs that overlap the ACRD MM0295-003 (46488) M MPX 13 113,361,712 113,646,000 284,289 gain CNVs that overlap the ACRD SK0305-004 (78621) F SPX 14 42,022,286 42,210,026 187,741 loss CNVs that overlap the ACRD SK0320-003 (79449) M MPX 14 45,537,581 45,653,418 115,838 loss CNVs that overlap the ACRD MM0225-004 (60826) M MPX 14 83,373,278 83,435,200 61,923 gain CNVs that overlap the ACRD MM0154-003 (56678L) F MPX 14 106,223,861 106,356,482 132,622 gain CNVs that overlap the ACRD NA0064-000 (63582L) M SPX 15 82,573,421 83,631,697 1,058,276 loss CNVs that overlap the ACRD MM0256-004 (46991) M MPX 15 87,922,400 87,993,909 71,510 gain CNVs that overlap the ACRD SK0266-003 (68257) M SPX 16 6,813,789 6,898,849 85,060 loss CNVs that overlap the ACRD NA0063-000 (60351) M SPX 16 73,397,667 73,657,067 259,400 loss CNVs that overlap the ACRD NA0095-000 (75414L) M SPX 16 74,576,356 74,613,000 36,645 loss CNVs that overlap the ACRD SK0284-003 (72687) F SPX 17 28,985,300 29,960,700 975,400 gain CNVs that overlap the ACRD SK0012-003 (58468L) M SPX 18 27,565,032 27,781,900 216,869 gain CNVs that overlap the ACRD SK0152-003 (41548L) M CHR 18 32,174,061 32,990,975 816,914 loss CNVs that overlap the ACRD SK0147-003 (47544L) F SPX 18 37,509,556 37,950,450 440,895 gain CNVs that overlap the ACRD SK0304-003 (78063) M SPX 18 46,101,841 46,218,000 116,160 gain CNVs that overlap the ACRD NA0138-000 (81816L) M SPX 18 69,282,461 69,330,584 48,124 loss CNVs that overlap the ACRD SK0023-003 (58096) M SPX 21 46,497,675 46,678,820 181,145 gain CNVs that overlap the ACRD NA0112-000 (72340) M SPX X 38,250,331 38,371,333 121,003 gain CNVs that overlap the ACRD SK0283-003 (72309) F CHR 4 44,762,996 44,858,504 95,508 gain CNVs that overlap the ACRD MM0010-005 (47372) M MPX 4 44,773,367 44,846,800 73,434 gain CNVs that overlap the ACRD NA0093-000 (66999) M SPX 4 44,773,367 44,846,800 73,433 gain CNVs that overlap the ACRD MM0109-003 (46486) F SPX 4 189,538,747 189,825,000 286,254 gain CNVs that overlap the ACRD SK0112-003 (46100) M MPX 4 189,580,553 190,228,000 647,447 gain CNVs that overlap the ACRD

Wide-ranging prevalence frequencies of cytogenetically detectable chromosomal abnormalities in ASD, and the inability of microarray scans to find balanced abnormalities, prompted karyotyping to be performed. Karyotyping (and FISH) also provided the ability to characterize the chromosomal context (e.g. ring chromosomes) of some of the CNV regions, something not possible using microarrays alone. Therefore, 313 unbiased idiopathic cases where blood was available were examined and 5.8% (18/313) cases were found to have balanced (11) or unbalanced (7) karyotypes (all unbalanced karyotypic changes (7) were also found by microarray analysis and are included in the CNV statistics). The genomic characteristics of all CNVs are shown in the Autism Chromosome Rearrangement Database (see FIG. 3). In this study, CNV loss and gain will typically equate to a standard deletion or duplication. In some cases a duplication of only part of a gene could lead to its disruption (Table 5), and there are also positional effects on gene expression to consider.

De Novo, Overlapping/Recurrent, and Inherited Structural Variants

Structural variants found in ASD cases were initially prioritized to possibly be etiologic if they were not in controls and, (i) de novo in origin (25 cases) (see Table 5 below), (ii) overlapping (27 cases at 13 loci) in two or more unrelated samples (see Table 7 below), (iii) recurrent (same breakpoints) in two or more unrelated samples (four cases at two loci), (iv) or inherited (the remainder). In a proof of principle analysis, CNVs were found at known ASD loci: NLGN4 and 22q, 15q, SHANK3 and NRXN1 in categories i, ii, iii, and iv, respectively. ASD structural variants found in controls (eg. NRXN1) could also be involved.

TABLE 5 De Novo Rearrangements in ASD cases FamID (DNA)¹ Sex Type Chromosome² Size (bp)³ CNV Genes⁴ Phenotype Comments⁵ 1 SK0181-004 (52191) M CHR (SPX) 3p14.1-3p13 (a) 5,346,900 loss   13 genes IQ = 107 t(6; 14)(q13; q21)( k) N/A none   11 genes Dysmorphology 2 SK0152-003 (41548) M CHR (MPX)⁶ 3p25.1-p24.3 (a) 1,409,600 loss   12 genes IQ = unknown 5p15.31-p15.2 (a) 3,429,389 loss    8 genes 12q12 (a) 422,842 loss    4 genes t(5; 7)(p15p13) (k) N/A none CDH18 3 SK0215-006 (58449) M CHR (SPX) 1p21.3 (a) 1,092,500 loss DPYD whole IQ = 38, SLI 4 SK0205-004 (56242) F CHR (SPX) 5p15.33-5p15.2 (k) 13,800,984 loss   46 genes IQ = unknown, Cri du chat 5 SK0083-003 (50800) M CHR (SPX) 7q31.1-q31.31 (k) 11,023,507 loss   25 genes IQ = 76 6 SK0131-003 (39989) F CHR (SPX) 7q31.1-q32.2 (k) 15,486,722 loss >50 genes IQ = 95, SLI 7 SK0243-003 (67941) M CHR (SPX) 15q23-q24.2 (k) 4,289,500 loss >50 genes IQ = unknown, SLI 8 SK0073-003 (57283) F CHR (SPX) 15q11.2-q13.3 (k) 11,922,600 gain >50 genes IQ = unknown 9 SK0245-005 (68517) M CHR (SPX) 15q11.2-q13.3 (k) 11,871,747 gain >50 genes IQ = unknown 10 SK0218-003 (60340) F CHR (MPX)⁴ 18q21.32-18q23 (k) 20,358,999 loss >50 genes IQ = unknown, seizures, dysmorphology 11 NA0039-000 (69736) F CHR (SPX) 22q13.31-q13.33 (k) 3,231,700 loss   41 genes IQ = unknown 12 NA0097-000 (82361) F CHR (SPX) Xp22.33-p22.31 (a) 5,825,311 loss   21 genes + NLGN4 IQ = unknown 13 SK0283-003 (72309) F CHR (SPX) 47, XX, ring chr1 (k) N/A gain >50 genes IQ = 38 14 SK0133-003 (46012 M CHR (SPX) t(5; 8; 17)(q31.1; N/A none    5 genes IQ = unknown q24.1; q21.3) (k) 15 NA0002-000 (52026) M SPX 7q36.2 (a) 66,462 loss DPP6 exonic IQ = unknown 16 SK0262-003 (68609) M SPX 8p23.3 (a) 791,089 gain DLGAP2 exonic IQ = unknown 17 MM0278-003 (57788) M SPX 12q24.21-q24.33 (a) 18,218,000 gain >50 genes IQ = 36 18 NA0067-000 (65344) M SPX 16q24.3 (a) 265,667 loss ANKRD11 exonic IQ = unknown 19 MM0088-003 (45562) F MPX 16p11.2 (a) 675,829 loss   28 genes IQ = 87 20 SK0102-004 (31899) M SPX 16p11.2 (a) 432,600 gain   24 genes IQ = 74, Epilepsy 21 SK0244-003 (69183) M SPX 21q22.3 (a) 353,936 gain    4 genes IQ = 80 22 MM0109-003 (46486) F SPX 20q13.33 (a) 1,427,661 gain   44 genes IQ = unknown 22q13.33 (a) 276,702 loss   13 genes + SHANK3 23 SK0119-003 (35190) M MPX⁴ 22q11.21 (a) 2,771,300 loss >50 genes IQ = 58, VCF syndrome 24 SK0297-003 (76066) M SPX-MZ 22q11.21 (a) 4,281,262 gain >50 genes IQ = 107, dysmorphology 25 SK0306-004 (78681) F SPX Xp11.23-11.22 (a) 4,643,367 gain >50 genes IQ = 87 ¹Table is sorted based on family type. Probands with abnormal karyotypes (CHR) (1-14) are separated from probands belonging to simplex (SPX) and multiplex (MPX) families with normal karyotypes (15-25). ²De novo event detected by either karyotype (k) or microarray (a) ³De novo CNV/translocation has been confirmed by at least one of karyotype, FISH, or qPCR. CNV size is based on array results. The breakpoints have not been accurately defined, and CNVs may be smaller or larger than posted. ⁴When only a single gene is involved if the CNV intersects (suggesting it may disrupt the gene) the term ‘exonic’ is used and if the CNV encompasses the entire gene the term ‘whole’ is used. ⁵For multiplex families the de novo events were not detected in affected siblings. **comment on case 25 that is also in Table 3(see entry #2

TABLE 6 Recurrent and overlapping loci in ASD Chromosome FamID (DNA) Sex Type¹ Size (bp)² CNV Origin Genes³ Phenotype Comments 1 2q14.1 SK0147-003 (47544) F SPX   478,370 loss Paternal DPP10 exonic IQ = unknown, NF1 SK0288-003 (75420) F SPX-MZ   105,120 gain Paternal DPP10 intronic IQ = 83 2 2q32.1 SK0306-004 (78681) F SPX    97,130 loss Unknown None IQ = 87 NA0030-000 (55240) M SPX   112,323 loss Unknown None IQ = unknown 3 6q22.31 MM0220-003 (61180) M MPX   318,000 gain Paternal PLN, c6orf204 whole IQ = unknown NA0025-000 (60490) M SPX   293,989 gain Paternal PLN, c6orf204 whole IQ = unknown 4 7q36.2 SK0190-003 (54742) M SPX  1,780,000 gain Maternal DPP6 whole IQ = 82 SK0115-003 (40555) M SPX   274,000 gain Unknown DPP6 exonic IQ = unknown SK0058-003 (59963) M MPX    16,788 gain Maternal DPP6 intronic IQ = 111 NA0002-000 (52026) M SPX    66,462 loss De novo DPP6 exonic IQ = unknown 5 8q11.23 SK0143-003 (36812) M SPX   285,200 gain Unknown UNQ9433 whole, IQ = 66 RB1CC1 exonic Apraxia, CHD, Seizures MM0236-004 (46475) M MPX   271,679 gain Unknown RS1CC1 exonic IQ = 99 6 9p24.1 SK0270-003 (71341) M SPX    38,900 loss Unknown none IQ = 91, SLI MM0103-003 (42387) M MPX    34,950 loss Paternal none IQ = 107 7 11p12 MM0272-003 (45563) M MPX   262,938 loss Maternal none IQ = 111, Seizures SK0167-003 (60966) F MPX   192,846 loss Unknown none IQ = 91 8 13q21.32 SK0023-003 (58096) M SPX   189,438 gain Unknown PCDH9 intronic IQ = 91, Seizures MM0299-003 (51674) F MPX   172,401 gain Paternal PCDH9 intronic IQ = 39 9 15q11.2-q13.3 SK0073-003 (57283) F CHR 11,922,600 gain De novo >50 genes IQ = unknown SK0245-005 (68517) M CHR 11,871,747 gain De novo >50 genes IQ = unknown 10 16p12.1 MM0109-003 (46486) F SPX  1,246,288 gain Maternal    8 genes IQ = unknown MM0289-003 (42267) F MPX   802,555 loss Maternal    5 genes IQ = 63 11 16p11.1 NA0133-000 (78119) F SPX   525,319 gain Maternal   29 genes IQ = unknown SK0102-004 (31899) M SPX   432,600⁴ gain De novo   24 genes IQ = 64, Epilepsy MM0088-003 (45562) F MPX   675,829 loss De novo   32 genes IQ = 87 12 22q11.2 SK0119-003 (35190) M MPX  2,771,300 loss De novo >50 genes IQ = 58, VCF syndrome SK0091-004 (46407) F MPX  4,281,262 gain Paternal >50 genes IQ = 126 SK0297-003 (76066) M SPX-MZ  4,281,262 gain De novo >50 genes IQ = 107, dysmorphology SK0323-003 (80022) M MPX   743,100 gain Unknown    7 genes IQ = unknown 13 22q13.31 SK0123-004 (60536) M MPX   601,528 gain Maternal none IQ = 93 MM0102-003 (47598) M MPX    80,380 loss Maternal none IQ = 70 ¹Families are grouped based on simplex (SPX), multiplex (MPX) and chromosomal abnormalities (CHR). Simplex families with affected monozygotic twins is denoted as SPX-MZ. The de novo cases also appear in Table 2 and some of the family pedigrees are shown in FIG. 2 and Supplemental FIG. 2. ²CNV size is based on array results. The breakpoints have not been accurately defined, and CNVs may be smaller or larger than posted. ³When only a single gene is involved if the CNV intersects (suggesting it may disrupt the gene) the term ‘exonic’ is used and if the CNV encompasses the entire gene the term ‘whole’ is used. ⁴CNV is only called by one algorithm

By testing parental DNA and validating CNVs, a de novo mutation rate of 7.1% (4/56) and 2.0% (1/49) was observed in idiopathic simplex and multiplex families, respectively. There was parental information for 13 of 18 cases discovered to carry cytogenetic abnormalities and 7 (6 simplex, 1 multiplex) of these were de novo in origin. Since only 1/7 (from a simplex family) of these was balanced and directly interrupting a gene, it was estimated that this class of rearrangements had much less of a contribution than CNVs to the total rate of de novo and structural variation in the present cohort.

The collective data identified 25 de novo cases (Table 5) and in three, two or more events were identified. Notably, in family SK0152 (FIG. 4 a) there were four de novo events. In MM019 (FIG. 4 b) there were two de novo deletions, one leading to haplo-insufficiency of SHANK3.

The 13 loci where overlapping ASD-specific CNVs were found are likely indicative of ASD-susceptibility since they arise in two or more unrelated families. In six, gains and losses often encompassing entire genes were observed at the same locus (Table 6) suggesting general gene dysregulation to be involved.

Using q-PCR or by assessing SNP patterns, 196 inherited CNVs (90 maternal and 106 paternal) were confirmed. No sub-grouping of these demonstrated obvious parent-of-origin effects (the two chromosome 15q11-q13 duplications detected were both de novo in origin). A 160 kb deletion was detected in a male inherited from a carrier mother, leading to a null PTCHD1 in the proband and his dizygotic twin brother (FIG. 4 c). There were also instances where apparently balanced inherited translocations were accompanied by de novo deletions in the offspring (eg. DPYD) (FIG. 4 d).

Candidate ASD-Susceptibility Genes and Loci Identified

New ASD candidates identified were those with a structural change (either de novo or found in two or more unrelated ASD cases, or for the X chromosome an allele being transmitted maternally from an unaffected carrier) specific to that gene, including ANKRD11, DLGAP2, DPP6, DPP10, DPYD, PCDH9 and PTCHD1 (Tables 5 and 6). As previously noted, NLGN4, SHANK3 and NRXN1 were also identified. The PCDH9 and NRXN1 genes are also found as CNVs in controls in the DGV (Database of Genomic Variants).

Additional positional candidate genes identified were those found interrupted by balanced cytogenetic breakpoints including NEGR1, PIP5K1B, GABRG1, KLHL3, STK3, ST7, SATB2 (Table 1). Moreover, 77 CNVs in the stringent dataset overlapped with the Autism Chromosome Rearrangement Database providing a second line of evidence for involvement (FIG. 2). For example, a 4.6 Mb de novo duplication at Xp11.23-11.22 was detected in a female SK0306-004 (Table 5) and a male in the database.

DPP6 and DPP10 emerge as being positional and functional candidates. DPP6 (˜1.5 Mb in size at 2q14.1) and DPP10 (˜1.3 Mb at 7q36.2) code for accessory trans-membrane dipeptidyl peptidase-like subunits that affect the expression and gating of Kv4.2 channels (KCND2). Kv4.2 channels function in regulation of neurotransmitter release and neuronal excitability in the glutamatergic synapse at the same sites where SHANK3 and the NLGN gene products are found. In addition, autism balanced breakpoints have been mapped near KCND2 at 7q31.

For DPP10 there are inherited CNV gains and losses (Table 5, FIG. 4). De novo and inherited CNVs were found at the multi-transcript DPP6 gene. A 66 kb de novo loss encompassing exons 2 and 3 is found in a male in family NA0002 (FIG. 4 e). In family SK0190, the male proband and an unaffected female sibling both carry a CNV gain inherited from an unaffected mother (FIG. 4 f) that encompassed the entire DPP6. A 270 kb gain was found in SK0115-003 that extends across the first exon (which may disrupt the functional gene) and SK0058-003 carries a maternally-inherited 16 kb intronic CNV gain (Table 1; FIG. 5).

Medical Genetics

Structural variants overlapping loci involved in medical genetic conditions including Waardenburg Type IIA (3p14.1), speech and language disorder (7q31), mental retardation (MR) (15q23-q24, 16p11.2) and velocardialfacial syndrome (VCFS) (22q13) were identified (Table 5), amongst others. Identification of the structural variant at these loci led to clinical re-assessment and either identification or refinement of the diagnosis, for additional syndromic features. Other instances (eg. SK0186-PTCHD1 deletion) (FIG. 4 c) prompted re-testing of the entire family and eventually a diagnosis of mild-ASD in a previously undiagnosed sibling. This family was then redesignated multiplex as opposed to simplex.

The identification of a de novo deletion (2.7 Mb) at 22q11.2 in two ASD brothers led to their re-examination and diagnosis for VCFS. The re-testing also further defined the siblings to be at opposite ends of the ASD spectrum (FIG. 6). Larger duplications (4.3 Mb) of this same region in two other ASD families (SK0289 and SK0091) did not cause VCFS (Table 6); however, in SK0091 the variant was inherited from a normal father and not found in an affected male sibling.

A recurrent ˜500 kb duplication at 16p11.2 in two ASD families (SK0102 and NA0133) (FIGS. 4 and 5) was also discovered. As with DPP6/DPP10 and 22q11.2, there were carriers of these structural variants without ASD. In a third family (MM0088), the proband has a larger 676 kb de novo deletion and it is only detected in one of two ASD siblings. (FIG. 4 g).

In sum, using the genome-wide scanning approach, numerous new putative-ASD loci (Tables 4 and 5, FIG. 2) were identified. Generally, ASD loci include (i) those that contain genes functioning in the PSD, (ii) and/or chromosomal regions previously shown to be involved in mental retardation, and (iii) involve dysregulation of gene expression.

CNVs that implicate ASD loci include the SHANK3, NLGN, and NRXN1-PSD genes and also identify novel loci at DPP6 and DPP10 (amongst others including PCDH9, RPS6KA2, RET from the full dataset) were identified.

Lastly, six unrelated ASD cases were identified (Table 6) that had either CNV gains or losses at the same locus which indicate that gene expression of genes in these regions are related to the development of speech and language and/or social communication in humans, as in SHANK3 and genes in the Williams-Beuren syndrome locus.

Example 2 PTCHD1 as a Marker of ASD

As set out above, a genome scan with Affymetrix 500K SNP Arrays was used to identify a CNV deletion on chromosome Xp22.11 that spans exon 1 of the PTCHD1 gene. Exon 1 is shown bolded in FIG. 7 spanning nucleotide positions 1-359. The Cdna sequence of the PTCHD1 gene (NM_(—)173495) as well as the amino acid sequence of the corresponding encoded protein is illustrated in FIG. 7 which illustrates a genomic size of:: 59325, an exon/coding exon count of 3 encoding a protein of 783 amino acids.

The deletion was determined to be an ˜156 kb deletion on Xp22.11 on a male proband. The physical position of this CNV is chrX:22,962,800-23,119,000 (UCSC 2004 Assembly). The deletion is flanked by SNP probes rs7055928 and rs1918560 (at 22.956 and 23.133 Mb from the Xp terminus, respectively). The most proximal and distal SNPs (from the Affymetrix SNP microarrays) within the deleted region, as determined by the SNP microarray analysis, are rs7879064 (23.119 Mb) and rs4828958 (22.972 Mb). PCR amplicons from within the deleted region were used to confirm the deletion by Qper (PCR primers and locations are given below). This deletion spans the entire exon 1 of the PTCHD1 gene (NM_(—)173495). Analysis of both Sty and Nsp chips data identified this event and was further validated using PCR and QPCR techniques. The following primers were used:

PTCHD-CNV1F ATTCGCAGTTCCTTCGTCTT (SEQ ID NO: 1) PTCHD-CNV1R AAAGTGGATTGATCGGTTCC (SEQ ID NO: 2) PTCHD-CNV2F GCTTGAGGACGTGTTTCTCC (SEQ ID NO: 3) PTCHD-CNV2R CTAGGAGAGGTGGCGCTCT (SEQ ID NO: 4)

This CNV is autism specific as it was not present in the Database of Genomic Variants (DGV) and in other controls. Furthermore, the segregation of this deletion was characterized in family and it was identified that the deletion was transmitted from a heterozygous mother. A male sibling also had language deficits.

Mutation screening of PTCHD1 in N=400 autism patients was conducted in the usual manner. The following primers were used:

PTCHD1-x1F AGCGTGCGCCTCGCCCT (SEQ ID NO: 5) PTCHD1-x1R TCCTTGTCCAGGAGGCTGGGA (SEQ ID NO: 6) PTCHD1-x1Bf GCGCCCGCTCTGCTCTA (SEQ ID NO: 7) PTCHD1-x1Br TCCTTGTCCAGGAGGCTGGGA (SEQ ID NO: 8) PTCHD1-x2-F GAATGTCCACCCTCTCCAAA (SEQ ID NO: 9) PTCHD1-x2-R AAGGCTACTCCTGGCCTTTT (SEQ ID NO: 10) PTCHD1-x3a-F CTTTGACCCAGTAGTCCCTCA (SEQ ID NO: 11) PTCHD1-x3a-R GCACAAACCCCTTGGTGTA (SEQ ID NO: 12) PTCHD1-x3b-F TGTGATTGGGTTTTACATATATGAGTC (SEQ ID NO: 13) PTCHD1-x3b-R AGGTCAGATTTGAAGGCACAG (SEQ ID NO: 14) PTCHD1-x3c-F AAAAATGCCCTGGAAGTGC (SEQ ID NO: 15) PTCHD1-x3c-R TGTGTGAATTCTCATAACAACTCCT (SEQ ID NO: 16)

The mutation screening revealed an I173V mutation.

Example 3 Identification of Additional Markers of ASD

By sequencing the entire coding region of PTCHD1 in 900 unrelated ASD cases, six missense mutations were identified in six unrelated ASD probands (Table 7, FIG. 8). For clinical details see Table 8.

TABLE 7 XCI Status No. of of Control Sex of Family Carrier Population Frequency Chromosomes Subject ID Exon Mutation Nucleotide Proband Transmission Type Mother Ancestry in ASD Tested Family 1 1 167-kb deletion, disrupts M Mother Multiplex Skewed European 1 in 427 2067 PTCHD1 gene at Xp22.11 (M = 769 F = 1298) Family 1 1 167-kb deletion, disrupts M Mother Multiplex Skewed European 1 in 427 2067 PTCHD1 gene at Xp22.11 (M = 769 F = 1298) Family 2 2 I173V 517A > G M Mother Multiplex Random European\Mixed 2 in 900  659 (M = 219 F = 220) Family 3 2 I173V 517A > G M Mother Simplex Random European 2 in 900  659 (M = 219 F = 220) Family 4 2 V195I 583G > A M Mother Simplex NC European 1 in 900  659 (M = 219 F = 220) Family 5 2 ML336-7II 1008-9GC > TA M Mother Simplex Random Asian 1 in 900  751* (M = 249 F = 251) Family 6 3 E479G 1436A > G M Mother Multiplex Random European 1 in 900  427 (M = 137 F = 145) Family 7 1 L73F 217C > T M Mother Multiplex NC Not Available 1 in 900  427 (M = 137 F = 145) *Out of 751 control chromosomes tested, N = 92 were Asian

TABLE 8 Subject ID Sex Mutations Clinical Details Family History Comments Family 1 M 167-kb del Meet ADI and ADOS-1 criteria for diagnosis of autism. Difficulty Maternal history of Severe colic with conversations, echoed words, repetitive interests, delay in social learning problem and during early use of language. Attention Deficit and Hyperactivity Disorder articulation difficulties. childhood (ADHD). No mental retardation (MR). Paternal history of ADHD Non-Verbal IQ = 42% ile like features. Family 1 M 167-kb del Meet ADI and ADOS-1 criteria for diagnosis of autism. Difficulty Maternal history of Severe colic with conversations, echoed words, repetitive interests, delay in social learning problem and during early use of language. Attention Deficit and Hyperactivity Disorder articulation difficulties. childhood (ADHD). No mental retardation (MR). Paternal history of ADHD Non-Verbal IQ = 23% ile like features. Family 2 M I173V Meet ADI and ADOS-1 criteria for diagnosis of autism. Highly Father had type II diabetes repetitive language and behaviour, motor mannerisms, extremely hyperactive, poor motor coordination and mental retardation, Lang: receptive = 40, <1% ile, expressive = 40, <1% ile Family 3 M I173V Meet ADI and ADOS-1 criteria for diagnosis of autism. Meet ADI No family history of PDD and ADOS-1 criteria for diagnosis of autism. ADI social score = 25, ADI communication score = 21, ADI Restricted, Repetitive, and Stereotyped Behavior Score = 11, ADI development score = 3, Normal IQ, M V195I Diagnosed with autism at the age of 3 years and 4 months. Meet ADI No family history of PDD FRX and head and ADOS-1 criteria for diagnosis of autism. Severe expressive and CT scan was receptive language delay. No dysmorphology observed. normal Family 5 M ML336-7II Meet ADI and ADOS-1 criteria for diagnosis of autism. ADI social Father died of leukemia Minor score = 26, ADI communication score = 14, ADI stereotype score = 5 thalassemia ADI development score: 4, ADOS social + communication score = 20, ADOS Restricted, Repetitive, and Stereotyped Behavior Score = 3, Some traits were observed that could be related to schizophrenia. Family 6 M E479G Diagnosed with high functioning autism. No family history of PDD Family 7 M L73F Meet ADI and ADOS-1 criteria for diagnosis of autism

All these mutations resulted in the substitution of highly conserved amino acids, and were inherited from unaffected carrier mothers. Based on in silico protein modeling, three mutations (L73F, I173V, V195I) are present in a predicted amino acid loop that sits outside of the cell membrane. This loop is posited to interact with the ligand, Hh. Another mutation, the 2-amino acid substitution ML336-337II was present within a predicted transmembrane domain. Finally, the E479G mutation was present within a predicted cytoplasmic amino acid loop. In five out of six families, these mutations segregated with the phenotype. Controls (439) were tested for the I173V and V195I mutations, 500 controls for ML336-337II, and 282 controls for L73F and E479G. None of these mutations were present in controls. Furthermore, the fact that these mutations were all maternally inherited to male probands, and were not observed in our control populations, indicates that the mutations are associated with ASD. In turn, it is reasonable to assume that these mutations contribute to the etiology of autism, and perhaps in-combination with other disease-related loci, give rise to the ASD phenotype.

Interestingly, in two of the ASD families reported in Tables 7/8 (Family-2 & Family-4), other ASD-related CNVs were identified. In family 2, in addition to I173V mutation, a de novo ˜1.0 Mb loss at 1p21.3 resulting in deletion of the entire DPYD gene (NM_(—)000110.3) was identified. DPYD encodes a rate-limiting enzyme, dihydropyrimidine dehydrogenase (DPD), involved in pyrimidine metabolism. Complete DPD deficiency results in highly variable clinical outcomes, with convulsive disorders, motor retardation, and mental retardation being the most frequent manifestations. In Family-4, in addition to the V195I mutation, a 66 Kb de novo loss at 7q36.2 was identified resulting in deletion of DPP6 exon 3, and 33 amino acids towards the N-terminal end of the DPP6 protein. These cases evidence digenic involvement in ASD.

The ability of these PTCHD1-mutants to repress Gli2 expression was compared with wild type to determine if there was loss of function in the mutants. NIH10T1/2 fibroblasts were transfected with CMV-empty vector, a Gli-responsive promoter fused to the Luciferase gene (Gli2 pro), β-Gal (normalization) and PTCHD1 mutant expression plasmids. A mild loss of function of at least the E479G and ML336-7II mutants resulted in increased expression of Gli2 compared to wild type. 

1. (canceled)
 2. (canceled)
 3. (canceled)
 4. (canceled)
 5. (canceled)
 6. (canceled)
 7. (canceled)
 8. (canceled)
 9. (canceled)
 10. (canceled)
 11. (canceled)
 12. (canceled)
 13. (canceled)
 14. (canceled)
 15. (canceled)
 16. (canceled)
 17. A method of determining the risk of ASD in an individual comprising: probing a nucleic acid-containing sample obtained from the individual for a genomic sequence mutation in at least one gene selected from the group consisting of PTCHD1, SHANK3, NFIA, DPP6, DYPD, DPP10, GPR98, PQBP1, ZNF41 and FTSJ1, wherein identification of a mutation that modulates the expression of at least one of said genes is indicative of a risk of ASD.
 18. A method as defined in claim 17, wherein the genomic sequence variation is in the PTCHD1 gene.
 19. A method as defined in claim 17, wherein the genomic sequence mutation is a deletion of at least a portion of exon 1 of PTCHD1.
 20. A method as defined in claim 17, wherein the genomic sequence mutation is an intronic gain in DPP10.
 21. A method as defined in claim 17, wherein the genomic sequence mutation is an exonic loss in DPP10.
 22. A method as defined in claim 17, wherein the genomic sequence mutation is an exonic loss encompassing at least a portion of exons 2 and 3 in DPP6.
 23. A method as defined in claim 17, wherein the genomic sequence mutation is a gain in DPP6 selected from at least one of the group consisting of the entire DPP6 gene, a 270 kb exonic gain in exon 1 and a 16 kb intronic gain.
 24. A method as defined in claim 17, wherein the genomic sequence mutation is a loss in the SHANK3 gene.
 25. A method as defined in claim 17, wherein the genomic sequence mutation is a loss of the DYPD gene.
 26. A method as defined in claim 17, wherein the genomic sequence mutation is at least one missense mutation in PTCHD1 resulting in at least one amino acid substitution in the encoded protein selected from the group consisting of L73F, I173V, V195I, ML336-337II and E479G.
 27. A method as defined in claim 17, wherein the genomic sequence mutation is selected from the group consisting of a deletion of at least a portion of exon 1 of PTCHD1; an intronic gain in DPP10; an exonic loss in DPP10; an exonic loss encompassing at least a portion of exons 2 and 3 in DPP6; a gain in DPP6 selected from at least one of the group consisting of the entire DPP6 gene, a 270 kb exonic gain in exon 1 and a 16 kb intronic gain; a loss in the SHANK3 gene; a loss of the DYPD gene; and at least one missense mutation in PTCHD1 resulting in at least one amino acid substitution in the encoded protein selected from the group consisting of L73F, I173V, V195I, ML336-337II and E479G.
 28. A method of determining the risk of ASD in an individual comprising: screening a biological sample from the individual for abnormal levels of at least one gene product expressed by a gene selected from the group consisting of PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1, wherein a determination that at least one of said gene products is expressed at a level that varies from the expression level in a healthy non-ASD individual is indicative of a risk of ASD.
 29. The method as defined in claim 28, wherein the biological sample is screened for abnormal levels of the PTCHD1 gene product.
 30. A method of determining the risk of ASD in an individual comprising: screening a nucleic acid-containing sample from the individual for at least one genomic sequence variation that modulates the expression of PTCHD1, wherein identification of at least one of said genomic sequence variations is indicative of a risk of ASD in the individual.
 31. A method as defined in claim 30, wherein the genomic sequence variation is in the PTCHD1 gene.
 32. A method as defined in claim 30, wherein the genomic sequence variation is a deletion of at least a portion of exon 1 of PTCHD1.
 33. A method as defined in claim 30, wherein the genomic sequence variation is at least one missense mutation in PTCHD1 resulting in at least one amino acid substitution in the encoded protein selected from the group consisting of L73F, I173V, V195I, ML336-337II and E479G. 